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Abstract: 
Breast cancer (BC) is one of the most commonly diagnosed cancers in women. Estrogen signaling 
and the estrogen receptors (ERα, ERβ) are implicated in breast cancer progression. Majority of 
breast cancers start out as estrogen dependent as a result of overexpression of ER-regulated genes. 
Estrogen deprivation therapy using anti-estrogens (AEs) and aromatase inhibitors (AIs) to block ER 
activity and arrest the estrogen-dependent growth of BC still represents the primary treatment for 
breast cancer patients. This approach, however, frequently fails and patients develop resistant breast 
cancer, which is almost untreatable. In this project we focused on synthesizing a potent coactivator 
binding inhibitors (CBIs) molecules that block ER activity through a different mechanism that may 
arrest the estrogen-dependent growth of BC and offer a solution to the existing resistance. Co-
activator binding inhibitors (CBIs) act by blocking the conformational change needed for DNA 
binding and gene expression. In this project set of compounds have been designed, synthesized 
through sequential substitution of the chlorine atoms of 2,4,6-trichloropyrimidine with amines or 
other nucleophiles. The synthesized compounds were purified using chromatography techniques, 
and characterized by (
1
H-NMR, 
13
C-NMR, FT-IR and MS (ESI)) spectroscopy. Some of these
compounds were screened for their inhibitory activity against the acute myeloid leukemia cells 
(Molm-13) cells. Two forms of Molm-13 had been used to evaluate the role of p53. In one case 
cells were transfected with empty vector and in the other the cells were tranfected with sh-p53 RNA 
(sh-p53). The viability of cells was determined using WST-1 assay. 
Initial results of the tested compounds demonstrated that MY12 (35) and MY3 (26) exhibited potent 
activities against the two forms of Molm-13 cell lines and have a dose dependent effect while the 
compound MY2 (25) showed no significant inhibitory action on the same cell lines. 
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1.1. General Introduction 
 
According to the American Cancer Society, the most common causes of cancer death in women 
worldwide are cancers of the lung and bronchus, breast, and colorectum.
[1]
 Each year breast cancer 
threatens the lives of hundreds of thousands of women and affecting countries at all levels of 
modernization. Breast cancer begins when cells in the breast's milk-producing glands or in the tubes 
(ducts) that take milk to the nipples acquire genetic changes that allow them to divide 
uncontrollably and to move around the body (metastasize). The uncontrolled cell division leads to 
the formation of a lump that can be detected by mammography (a breast X-ray) or by manual breast 
examination.[2] Most DNA mutations are acquired rather than being inherited. These acquired 
mutations of oncogenes and/or tumor suppressor genes may result from environmental, like cancer-
causing chemicals or radiation. But so far, the causes of most acquired mutations that could lead to 
breast cancer are still unknown.
 [3]
 Most breast cancers have several acquired gene mutations. Tests 
to spot acquired gene changes may help doctors more accurately predict the outlook for some 
women with breast cancer. For example, tests can identify women whose breast cancer cells have 
too many copies of the HER2 oncogene. These cancers tend to be more aggressive. At the same 
time, drugs have been developed that specifically target these cancers and improve outcomes for 
patients.
[4]
 
Genetic factors such as inherited DNA mutations can dramatically increase the risk for developing 
certain cancers. For example, there is extensive evidence that mutated BRCA genes (BRCA1 and 
BRCA2), which are tumor suppressor genes, could be inherited and people with such mutants are 
considered under real risk to develop breast and ovarian cancer.
[5]
 BRCA genes are considered 
“high-penetrance” because they often lead to cancer. Although many of the women with high-
penetrance mutations develop cancer, most cases of cancer (including breast cancer) are not caused 
by this kind of mutation. Women have already begun to benefit from advances in understanding the 
genetic basis of breast cancer. Genetic testing can identify some women who have inherited 
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mutations in the BRCA1 or BRCA2 (or less commonly in other genes such as PTEN or TP53). These 
women can then take steps to reduce their risk of developing breast cancers and to monitor changes 
in their breasts carefully to find cancer at an earlier, more treatable stage.
[6], [7]
 
Many of the known breast cancer risk factors such as sex, age, family history, early menarche, and 
late menopause, are not modifiable and cannot be changed. However, other factors associated with 
increased breast cancer risk, including postmenopausal obesity, use of combined estrogen and 
progestin menopausal hormones, cigarette smoking, and alcohol consumption are modifiable. Many 
risk factors affect lifetime exposure of breast tissue to hormones (early menarche, late menopause, 
obesity, and hormone use). Reproductive hormones are also thought to influence breast cancer risk 
by increasing cell proliferation, thereby increasing the likelihood of DNA damage, as well as 
promotion of cancer growth.
 [3]
 
Breast cancer is frequently hormone-dependent. That is: hormones stimulate the cancer cells to 
grow. Vice versa this means that the growth of the cancer cells can be down regulated by the 
oppositely active hormones or so-called antihormones. Therefore, a hormone therapy (HT) is 
possible as an adjuvant treatment on breast cancer as well as with metastases. Today surgery, radio-, 
chemo-, and hormonal therapy form a common combination which has to be coordinated for each 
individual treatment.
[8]
 
 The steroid hormone 17β-estradiol (E) is a key regulator of growth, differentiation, and function in 
a wide array of target tissues, including the male and female reproductive tracts, mammary gland, 
and skeletal and cardiovascular systems. It's predominant biological effects are mediated through 
two distinct intracellular receptors, ERα and ERβ, each encoded by unique genes.[9] Estrogen plays 
a significant role in the development and growth of hormone-dependent breast cancer.
[10]
 It was 
reported that approximately 75% of human breast cancers (BCs) are hormone-dependent and are 
Estrogen Receptor (ERα) positive.[11] Progesterone receptor (PR) and Androgen receptor (AR) are 
also reported to be expressed in breast cancer and were proposed as potential therapeutic targets in 
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Estrogen Receptor alpha (ERα) negative breast cancers that retain AR. Patients with (ER) and (PR) 
positive breast cancer can be treated with hormone therapy (HT) to inhibit ER signaling pathway.
[12]
 
HT uses three approaches:  (a) antagonizing ER function with antiestrogens such as selective ER 
modulator (SERM) like tamoxifen; (b) reducing levels of estrogen with aromatase inhibitors (AIs); 
or (c) down-regulating ER levels with pure antiestrogens.
[13]
 Despite the high level of success of 
HT, many BCs acquire resistance. The potential mechanisms for either intrinsic or acquired 
endocrine resistance are still poorly comprehended. Therefore identifying the factors and pathways 
responsible for this resistance, defining ways to overcome it, and improving treatment options with 
new therapeutic agents that act in new and alternative pathways are  important diagnostic and 
therapeutic challenges in current breast cancer research and treatment.
[14]
 
Medicinal chemistry plays a central role in discovery of novel anticancer drugs. Pyrimidine either 
as substituted or fused scaffolds reported in wide range of bioactive moieties including anticancer. 
The activities of pyrimidine-based  anticancer agents is induced through various mechanisms that 
includes antimetabolites, protein kinase inhibitors such as cycline dependent kinases  (CDKs), 
phosphatidylinositol 3-kinase inhibitors (PI3K), tyrosine kinase inhibitors (TKIs), or as coactivator 
binding inhibitors (CBIs).
[15]
 (Table 1.1) below shows pyrimidine based structures with different 
anticancer targets. CBIs are small molecules that have the ability to disrupt the protein–protein 
interaction and inhibit gene transcription in specific receptors like nuclear receptors (NR). The 
nuclear receptor (NR) includes estrogen receptor (ER), androgen receptor (AR), thyroid hormone 
receptor (TR), retinoic acid receptors (RAR and RXR) and vitamin D receptor. It is believed that all 
members of the NR super family evolved from a common ancestor, so there are some similarities in 
structure and function common to all NRs.
[16]
 The disruption of protein-protein interactions by 
using CBIs can be used as a method to treat medical conditions including inflammation, 
Alzheimer's disease, viruses and cancer.
[17]
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 In hormone-dependent breast cancers CBIs that directly disrupt the estrogen or/and androgen 
receptor/steroid receptor coactivator (SRC) interaction is believed to act as effective alternative 
approach to inhibit estrogen and androgen signaling and inhibit cancer growth that are resistant to 
conventional endocrine therapies.
[18]
 Based on a pyrimidine-core system new CBIs would be 
synthesized and exploited as alternative approach to inhibit estrogen and androgen signaling.  These 
(CBIs) designed to bind in the hydrophobic coactivator groove on the surface of ER and disrupt the 
interaction between ER and SRC proteins.
[19]
  
Breast cancer remained the most common cancer in women and its incidence continues to rise. 
Nonetheless, mortality is falling, partly as a result of earlier diagnosis through mammographic 
screening, improved surgical techniques and attention to margins, improved delivery of 
radiotherapy, and better adjuvant medical therapies.  
 
Table 1.1: Targets (Enzymes or Receptors) Involved in Anticancer Effects of the Patented   
Pyrimidines and their Biological Significance.  
Class Target 
Enzyme/Receptor 
Biological Significance 
Fused pyrolo pyrimidines EGFR, HER2, HER3 
and HER4 type 1 
receptor tyrosine 
kinases 
Suppression of cell death 
Fused pyrimidines Phosphatidylinositol-
3 (PI3) kinase 
Increases level of 
phosphatidylinositol-3,4,5-
triphosphate (PIP3) 
Pyrimidine derivatives PI3 kinase Phosphorylation of 
phosphatidylinositol (PI) 
Pyrimidines Lysophosphatidic 
acid acyltransferase β 
(LPAAT β) 
Catalyses the acylation of 
lysophosphatidic acid (LPA) to 
phosphatidicacid (PA) 
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Pyrimidines Nucleoside 
phosphorylases and 
Nucleosidases 
Inhibition of phosphorylation 
caused by MTAP and 
phosphorylytic cleavage of ribo 
and deoxyribonucleosides 
catalysed by PNP 
Fused pyrrolo pyrimidine B-Raf V600E, C-Raf, 
Fms, Kdr,Kit and 
TrkA kinases 
Propagation of biochemical 
signals in diverse biological 
pathways 
Pyrazolo[3,4d]pyrimidines EGFR Phosphorylation of tyrosine 
amino acid in proteins 
2,4,6-Trisubstituted 
pyrimidines 
PI3 kinase Phosphorylation of 
phosphatidylinositol (PI) 
Heteroalkyl linked 
pyrimidines 
CDK2, FLT3, JAK2 
and JAK2V617F 
Regulation of cell growth and cell 
division 
Pyrimidines EphB4, EphA2 
(receptor tyrosine 
kinases) 
Phosphorylation of tyrosine 
residues within an autoinhibitory 
juxtramembrane region 
Pyrimidines Cdc25A, Cdc25B 
protein phosphatases 
Activation of cyclin-dependent 
kinase (CDK) by 
dephosphorylating tyrosine and 
threonine residues 
4-Aryl-2-anilinopyrimidines PLK 
 
Control of mitotic entry of 
proliferating cells and regulation 
of many aspects of mitosis 
Substituted pyrimidines PI3 kinase Phosphorylation of 
phosphatidylinositol (PI) 
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Pyrrolo[2,3-d]pyrimidines Heat shock protein 
90 (Hsp90) 
Assistance of protein folding and 
enhancement of cell survival 
during stress conditions 
Pyrazolo[1,5-c]pyrimidines Cyclin-dependent 
kinase (CDK 2,4) 
Progression of G1 to S phase of 
cell cycle and a key component of 
G1 checkpoint 
Fused pyrimidines AKT Regulation of transcription, 
translation, growth and survival 
5,7-Disubstituted-3-
isopropylpyarazolo[4,3-
d]pyrimidines 
Platelet derived 
growth factor 
(PDGF) 
Induction of vascular smooth 
muscle proliferation 
Pyrimidines ODCase Catalysis of decarboxylation of 
OMP to UMP 
Cyclopenta[G]quinazolines Thymidylate 
synthase (TS) 
Catalysis of the methylation of 
deoxyuridine to thymidine 
monophosphate 
Substituted pyrimidines Raf-1 kinase, 
VEGFR-2 
Activation of ras signal 
transduction pathway; Formation 
of new blood vessels 
Pyrimidine indoles ATR kinase Regulation of firing of replication 
origins and repair of damaged 
replication fork during S phase 
Amino pyrimidines Focal adhesion 
kinase (FAK) 
Transduction of signals 
transmitted by integrins 
4-Morpholinopyrido [3,2-
d]pyrimidines 
PI3 kinase Phosphorylation of 
phosphatidylinositol (PI) 
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4-Aryl-2-aniliopyrimidines AuroraB, PLK4, 
PLK1, PLK2,PLK3, 
CDK1, CDK4, 
GSK3b 
Chromosome alignment; control 
of mitotic entry of proliferating 
cells; regulation of cell division; 
regulation of nuclear factor Kb 
nuclear activity 
Pyrido[2,3-d]pyrimidin-7-
ones 
C-Raf, B-Raf Potential check point for cancer 
related signal transduction 
Pyrrolo[3,4-d]pyrimidines Abl, Src tyrosine 
kinase 
Phosphorylation of tyrosyl 
residues of proteins regulate cell 
growth and differentiation 
2,7-Substituted thieno[3,2-
d]pyrimidines 
Focal adhesion 
kinase (FAK) 
Regulation of migration, 
proliferation and survival of cells 
by regulating the signal 
transduction system of integrin 
and growth factors 
4-(Selenophen-2(or 3)-
ylamino)pyrimidine 
EGFR Cell proliferation, survival 
promotion and apoptosis 
inhibition 
2,4-Diamino-6,7-dihydro-
5Hpyrolo[2,3]pyrimidine 
FAK/Pyk2 (non 
receptor tyrosine 
kinases) 
Transduction of signal from a 
group of stimuli to control cell 
proliferation, migration and cell 
survival 
Pyrimidines VEGFR Phosphorylation of the tyrosine 
residues in proteins involved in 
regulation of cell growth, 
differentiation and survival 
Biarylpyrimidines CDK 9 Cell cycle growth and cellular 
transcription 
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This table adapted from "Anti-Cancer Pyrimidines in Diverse Scaffolds: A Review of Patent 
Literature." Recent patents on anti-cancer drug discovery 10 (1): 23-71 Kaur, R., P. Kaur, et al. 
(2015).
[15]
 
1.2. Chemistry of Pyrimidine 
 
Pyrimidine is a six-member aromatic heterocyclic that composed of four carbon and two 
nitrogen atoms at positions 1 and 3 of the ring (Figure 1.1) (2).
[20]
 It is isomeric with two other 
forms of diazines, 1,2-diazine (pyridazine) (1), 1,4-diazine (pyrazine) (3) (Figure 1.1). 
Pyrimidines as other diazines are important natural constituents and building block with high 
availability in living organisms.
 
Arguably the most important function of pyrimidines is 
construction of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).Three nucleobases are 
pyrimidine-based thymine (4), cytosine (5) and uracil (6) (Figure 1.1).
[21]
 The first pyrimidine 
derivative, alloxan (7) (Figure 1.1), was isolated in 1818 by Gaspare Brugnatellilpg by oxidation 
of uric acid with nitric acid  and known for its diabetogenic action in a number of animals.
 [22, 23]
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Figure 1.1: Structure of Diazines.pyridazine (1), pyrimidine (2), pyrazine (3); DNA, RNA 
pyrimidine building blocks: thymine (4), cytosine (5), uracil (6) and alloxan (7). 
 
 
Diaminopyrimidines 
Hsp90 Assistance of protein folding and 
enhancement of cell survival 
during stress conditions 
2,4,6-Trisubstituted 
pyrimidines 
Nuclear receptor 
(NR) 
inhibit gene transcription 
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Pyrimidine nucleus constitutes central part of natural products (Fig 1.2). B vitamins thiamine (8), 
riboflavin (9), and folic acid (10), antibiotics like bleomycin (11). A variety of natural products 
such as alkaloids from plants and marine organisms also contain pyrimidine ring system 
including hypoxanthine (12), xanthine (13) found in tea, caffeine (14), theophyline (15) 
constituents of tea leaves and theobromine (16) that found in cocoa beans.
[24]
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Figure 1.2: Natural compounds containing pyrimidine. Thiamine (8), riboflavin (9), folic acid 
(10), bleomycin (11), hypoxanthine (12), xanthine (13) caffeine (14), theophyline (15), and 
theobromine (16). 
 
1.3. Therapeutic Potential of Pyrimidines Derivatives 
Large array of pyrimidine derivatives possess a variety of pharmacological properties including 
anticancer, antibacterial, antifungal, antileishmanial, antiviral, anti-inflammatory, analgesic, 
antihypertensive, antipyretic, antidiabetic, antiallerggic, anticonvulsant, antioxidant, 
antihistaminic,  herbicidal and many of pyrimidines derivatives are reported to possess potential 
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central nervous system (CNS) depressant properties and also act as calcium channel blockers.
[25]
 
Given below in (Table 1.2) is a brief account of various modifications reported on pyrimidine 
nucleus, specifically fused and substituted pyrimidines which showed a variety of biological and 
pharmacological activities. 
Table 1.2: Pyrimidine based structures with different biological structures. 
 
 
Number 
 
Pyrimidine 
Derivative 
 
Structure 
 
Biological Activity 
17 Trimethoprim N
NH2N
NH2
O
O
O
 
Antibacterial (dihydrofolate 
reductase inhibitor (DHFRI)
[26]
 
18 Sulfadimidine 
S
O
O
N
H
N
N CH3
CH3
H2N
 
Sulfonamide antibiotic 
(Dihydropteroate synthetase 
inhibitor) 
[25]
 
19 Vidarabine 
O
OH
HO
HO
N
N
N N
NH2
 
Antiviral activity against Herpes 
Simplex Viruses (HSV) 
[27]
  
20 Acyclovir 
N
N
HN N
OO
HO
NH2
 
Antiviral activity against HSV, 
and varicella-zoster virus (VZV) 
[25]
 
21 Zidovudine 
NHN
O
O
CH3
O
HO
N
N+
-N
 
Anti-HIVactivity 
[25]
 
22 5,6-Dihydroxy-2-
phenylpyrimidine-
4-carboxylic acid 
N
N
OH
OH
OH
O  
Antihepatitis C virus (HCV) 
activity 
[28]
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23 5-Flucytosine NHN
O
F
H2N
 
Antifungal 
[29]
 
24 Voriconazole 
OH
N
N
N
NN
F
F
F
 
Antifungal 
[25]
  
25 Pyrimethamine 
N
NH2N
H2N
CH3
Cl
 
Antimalarial activity (DHFR 
dihydrofolate reductases  
inhibitor of malarial 
plasmodia
[30]
 
 
26 
(4,6-Dipiperidin-1-
yl-pyrimidin-2-yl)-
[4 methylsulfanyl-
6-(3,4,5-
trimethoxy-
phenyl)pyrimidin-
2-yl]-amine 
NN
NH
NN
NN
SCH3
H3CO
H3CO
H3CO
 
 
Antileishmanial activity 
[31]
 
    27  Epirizole 
NN
H3C
N
N
H3C
O
CH3
O
CH3
 
Antipyretic, analgesic, and anti-
inflammatory activity 
(NSAID)
[23]
 
28  Dulcerozine 
NN
N
N
H3C
O
H3C
O
CH3
 
Anti inflammatory 
[32]
 
   29  Barbituric acid NHHN
O O
O
 
Aentral nervous system (CNS) 
depressants. sedative-hypotic 
and anticonvulsant 
 [33]
 
    30 Phenobarbital 
N
H
HN
O
O
O
 
Aedative-hypotic and 
anticonvulsant.
[33] 
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    31  2,4,6-triamino   
pyrimidines NN
NX
NH
H3CO
 
Antiepileptic pyrimidines 
agents
[34]
 
     32 Buspirone 
N OO
N
N N
N
 
Anxiolytic 
[23]
 
  33 Mezilamine 
N
NS O
N
F
F
 
 
Antipsychotic agent 
[23]
  
    34 Piribedil 
N
N O
N
ON
F
 
Antiparkinsonian drug which 
acts as a dopamine D2 and D3 
receptor agonist 
[23]
  
   35 Sodium thiopental HN
N
OH3C
CH3
CH3
OSNa
+
_
 
Rapid-onset short acting gereral 
anesthetic  
[33]
 
    36 
4-(4-Chloro-
phenyl)-2-
ethanesulfonyl-6-
trifluoromethyl-
pyrimidine 
NN
F
F
F
S OO
H3C
Cl 
Insulinotropic effects (GLP-1 
receptor activator) 
[35]
 
    37  Xanthines 
H
N
NN
H
HN
O
O
 
Adenosine Receptor 
Antagonists
[23]
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    38  (8-(noradamantan-
3-yl)-1,3dipropyl 
xanthine) 
{KW-3902} 
NH
N
N
O
N
O
H3C
CH3
 
Selective adenosine A1 receptor 
antagonist to treat acute renal 
failure, hypertension and induce 
dieresis. It has a partial 
protective effect against renal 
vasoconstriction during 
hypoxemia.
[36]
  
 
39 
3-(3-Hydroxy-
propyl)-8-[2-(3-
methoxy-phenyl)-
vinyl]-7-methyl-1-
prop-2-ynyl-3,7-
dihydropurine-2,6-
dione (MSX-2) 
N
N
N
O
N
O
O
OH
 
 
A2A adenosine receptor 
antagonist 
[37]
   
40 
2-amino- 4-(2-
furanyl)-5-(4-
pyrimidinyl)pyrimi
dine (LAS38096) 
N
N
N
N
O
H2N  
A2B adenosine receptor 
antagonist 
[37]
    
    41 
N-(2-
methoxyphenyl)- 
N-[2-(3-
pyridyl)quinazolin-
4-yl]urea 
N
O
NH2
N
N
N
O
H3C
 
A3 adenosine receptor 
antagonist 
[38]
 
    42 Minoxidil N+N
H2N
NH2N
O-
 
Antihypertensive 
[23]
  
   43  Propylthiouracil HN
N
O
HS  
Antithyroid 
(antihyperthyroidism)
[23]
 
 
    44 Thonzylamine 
N
N
N
NO
 
Antiallergic H1antihistamine 
[39]
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1.4. Pyrimidines and Pyrimidine Derivatives as Anticancer Agents  
Human cells have the capacity to salvage purines and pyrimidines for the synthesis of 
deoxyribonucleotides that are used for DNA synthesis, and analogues of these nucleotide 
precursors have proven to be an important class of anticancer agents.
[40]
 There are a total of 14 
purine and pyrimidine antimetabolites that are approved by the FDA for the treatment of cancer, 
which account for nearly 20% of all drugs that are used to treat cancer. Some of the first 
compounds approved by the FDA for the treatments of cancer were in this class of compounds is 
6-mercaptopurine (45) (Figure1.3), that approved for commercial release in September, 1953 for 
the treatment of childhood leukemia, where it is curative and is still the standard of treatment for 
this disease. [41] The chemotherapeutic efficacy of pyrimidine derivatives is related to their ability 
to inhibit vital enzymes responsible for DNA biosynthesis as dihydrofolate reductase (DHFR), 
thymidylate synthetase (TSase), thymidine phosphorylase (TPase) and reverse transcriptase 
(RTase). Or inhibit proteins that activate the signal transduction pathway as kinases proteins to 
act as CDK inhibitors, TNF-α inhibitors, Abl tyrosine protein kinase inhibitors, PI-3 kinase 
inhibitors, and cytokines inhibitors.
[42]
 
Other pyrimidine-based anticancer drugs in clinical use are shown in (Figure1.3). Fused 
pyrimidine containing such as cladribine (46), clofarabine (47), fludarabine (48), gefitinib (49), 
erlotinib (50), substituted pyrimidines found in capecitabine (51), cytarabine (52), decitabine 
(53) 
[43], [44]
 bafetinib (54), imatinib mesylate (55) and nilotinib (56) are examples of 2,4-
disubstitutedpyrimidies that represent as  potent tyrosine kinase inhibitors with significant 
efficacy as first- or second-line treatment in patients with chronic myeloid leukemia. Dasatinib 
(57) which also used for leukemia treatment is 2,4,6-triusubstituted pyrimidine compound. 
[45]
 
Due to the great potential of activities of pyrimidines and its derivaties in cancer treatment, we 
planned to synthesize new various 2,4,6 trisubstituted pyrimidine derivatives and evaluate the 
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intermediate compounds (2,4-disubstituted pyrimidines) and the final compounds (2,4,6-
trisubatituted pyrimidines). 
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Figure 1.3: potent anticancer agents contain pyrimidine moieties. 6-mercaptopurine (45), 
cladribine (46), clofarabine (47), fludarabine (48), gefitinib (49), erlotinib (50), capecitabine 
(51), cytarabine (52), decitabine (53), bafetinib (54), imatinib mesylate (55), nilotinib (56) and 
dasatinib (57). 
 
1.5. Pyrimidine as a Co-activator Binding Inhibitors (CBIs) of Nuclear Receptors (NR) 
1.5.1. Nuclear receptor structure and mechanism of action  
Nuclear receptors NR are a class of proteins found within cells; they function as ligand-activated 
transcription factors that regulate the expression of target genes to affect processes as diverse as 
development, reproduction, and general metabolism.
[46] 
 NRs work in concert with coactivators 
and corepressors to activate and suppress target gene expression.
[47]
 These proteins were first 
recognized as the mediators of steroid hormone signaling and provided an important link 
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between transcriptional regulation and physiology. In the mid-1980s, the steroid receptors were 
cloned and found to exhibit extensive sequence similarity.
[46, 48]
 The subsequent cloning of other 
receptor genes led to the unexpected discovery that there were many more nuclear receptor–like 
genes than previously suspected. Today, the human genome is reported to contain 48 members 
of this transcription factor family.
[49], [50]
 The nuclear receptor superfamily can be divided into 
three groups of receptors. The first group (class I) includes the steroid receptors (estrogen 
receptor ER, progesterone receptor PR, androgen receptor AR, glucocorticoid receptor GR, and 
mineralocorticoid receptor). These steroid receptors bind to DNA as homodimers and recognize 
palindromic response elements (5’-TGTTCT-3’ sequence). In the absence of bound ligand, 
steroid receptors are coupled to a large multiprotein complex (heat-shock proteins), including 
Hsp90, Hsp56, Hsp70, and p23. This complex maintains the receptors in a conformation able to 
bind ligand, and sequesters the receptors to the cytoplasm. In this state, the receptors are unable 
to influence the rate of transcription of their cognate promoters. Upon ligand binding, the steroid 
receptors dissociate from the heat-shock proteins Hsps , homodimerize, and translocate to the 
nucleus, where they bind in a head-to-head arrangement to the  DNA response elements.
[51],[52] 
[53]
 (Figure1.4 (a)). The second group of nuclear receptors (class II) includes retinoic acid 
receptors RAR, thyroid hormone receptors TR, and the vitamin D3 receptor VDR. These 
receptors are found strictly in the nucleus and form heterodimers with the receptor for 9-cis 
retinoic acid (RXR) and do not avidly interact with heat-shock proteins Hsps. Some unliganded 
NRs of this class may interact with DNA and act as transcription repressors. This may be the 
result of interaction with co-repressor proteins. Hormone binding induced conformational 
changes which facilitate interactions with coactivator proteins that remodel chromatin, controls 
polymerase binding and the expression of target genes (Figure 1.4 (a)). 
[54]
 The third group (class 
III) consists of orphan receptors, so-called because the endogenous ligands, target genes, and 
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physiological functions for these proteins are not currently identified. Orphan receptors can 
function as homodimers or monomers.
[52]
  
The nuclear ligand-regulated receptors have been successful targets for drugs treating a variety 
of human diseases. Primary examples include estrogen receptor (ER), the target for tamoxifen in 
breast cancer therapy; glucocorticoid receptor (GR), the target for dexamethasone and 
prednisolone as anti-inflammatory therapies; and peroxisome proliferator activated receptors 
(PPARs) such as PPARg, which is the target for rosiglitazone in type 2 diabetes therapy.
[55]
 
 
Figure 1.4: Structural and functional organization of nuclear receptors (a) Basic mechanism of 
nuclear receptors. (b) Nuclear receptor structure. Adapted from Targeting Nuclear Receptors with 
Marine Natural Products (Yang, 2014)
[56]
 
  
Members of the NR superfamily share a similar modular structure with functionally distinct 
domains (Figure 1.4 (b)), including a N-terminal A/B domain includes activation function-1 
(AF-1) region and central DNA-binding domain (DBD). However, the primary target for drug 
discovery is the C-terminal ligand binding domain (LBD), which contains the activation 
function-2 (AF-2) surface that serves as a binding site for coregulator proteins.
[56]
 The nuclear 
receptor LBD is the segment of the receptor which changes its conformation upon lipophilic 
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ligand binding; it is the physiologic binding site for natural ligands such as 17β estradiol (ER), 
cortisol (GR), and 1a,25-dihydroxyvitamin D3 (vitamin D receptor; VDR).
[57]
  Table (1. 3) 
below contains some types of nuclear receptors with therir ligands and biological roles in the 
body. 
Table 1.3:  Some types of nuclear receptors and biological roles in the body. 
NR Name NR Ligand Role of NR 
 
Estrogen Receptor (ER) 
ERα and ERβ 
17β-estradiol 
(estrogen (E)) 
Regulation of growth, differentiation, and 
function in a wide array of target tissues, 
including the male and female 
reproductive tracts, mammary gland, and 
skeletal and cardiovascular systems.
[58]
 
 
Progesterone Receptor (PR) 
PR-A and PR-B 
Progesterone 
Preparing the uterus endometrium for 
embryo implantation. It also suppresses 
milk protein synthesis in the mammary 
gland during pregnancy and regulates the 
outgrowth of alveolar structures in the 
mammary gland.
[59]
 
 
Androgen Receptor (AR) 
Testosterone & 5α-
dihydrotestosterone 
(DHT) 
Differentiation of the reproductive organs 
into the male phenotype, induces the 
secondary sexual characteristics, maintaine 
male skeletal integrity, development & 
maintenance of normal prostate.
[53, 60]
 
 
Glucocorticoids Receptor (GR) 
Glucocorticoids 
(cortisol) 
Regulation of glucose metabolism 
(gluconeogenesis), inhibition of bone 
formation, anti-inflammatory and 
immunosuppressive actions.[61] 
 
Mineralocorticoids Receptor 
(MR) 
Aldosterone 
control sodium reabsorption and blood 
pressure.[61]  
   Retinoic acid receptors 
(RARs) 
 Retinoid X receptors (RXRs). 
Retinoic acid 
Essential for reproduction, embryonic 
development, epithelial differentiation, 
immune function, vision and homeostasis. 
Regulate of epidermal cell growth and 
differentiation.
[62]
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1.5.2. Nuclear receptor coregulator  
Transcriptional coregulators have been revealed as the principal regulators of gene expression by 
directly interacting with and modulating the activity of essentially all nuclear receptors (NRs) and 
transcription factors.
 [52]
 On the basis of their functional output, coregulators can be sorted into two 
Vitamin D receptor (VDR) 
Calcitriol (1,25-
dihydroxyvitamine) 
Essential role in mineral metabolism, 
skeletal health and immunity, cell 
proliferation and differentiation.
 [63]
 
 
Peroxisome proliferator-
activated receptors (PPARs)  
PPARα, PPARδ/β, and PPARγ 
Thiazolidinedione 
Regulate lipid metabolism, glucose 
homeostasis, cellular differentiation, and 
inflammatory response.[64] 
 
Liver X receptors (LXRs)  
LXRα and LXRβ 
Oxysterols 
Lipid metabolism, including cholesterol 
and fatty acids homeostasis; 
steroidogenesis; glucose homeostasis; 
inflammation and immunity,
[65]
 
antidiabetic properties through suppression 
of hepatic gluconeogenesis and enhance 
peripheral glucose uptake.
[66]
 
 
Estrogen-Related Receptors   
(ERRs)                                
ERRα, ERRβ, and ERRγ 
Orphan NR               
No identifide ligand 
Regulating cellular metabolism through the 
regulation of genes involved in glycolysis, 
oxidative phosphorylation, and 
tricarboxylic acid cycle.
[67]
 
 
Chicken Ovalbumin Upstream 
Promoter Transcription Factors      
(COUP-TFs)               COUP-
TFI  and COUP-TFII 
Orphan NR               
No identifide ligand 
Regulation of several important biological 
processes, such as neurogenesis, 
organogenesis, cell fate determination, and 
metabolic homeostasis.
[68]
 
 
Nerve growth factor IB-
like receptor (NGFI-B) 
Orphan NR               
No identifide ligand 
Controling of inflammation, proliferation, 
apoptosis, thrombosis, and 
angiogenesis.
[69]
 
 
‘‘Dosage-sensitive sex reversal, 
adrenal hypoplasia critical 
region, on chromosome X, gene 
1’’ (DAX1) 
Orphan NR               
No identifide ligand 
Regulation of development and function of 
both the hypothalamic-pituitary-adrenal 
(HPA) and hypothalamic-pituitary-gonadal 
axes. Act as an anti-Sry factor in the 
process of gonadal sex differentiation.
[70]
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major classes: coactivators, which are associated with agonist-bound NRs to induce gene 
expression, and corepressors, that selectively repress gene expression through interaction with 
unliganded or antagonist-bound NRs. 
[9] [71] Transcriptional induction is an ordered and dynamic 
process in which a NR first receives a signal from its cognate ligand and then translocates to 
specific DNA sequences in the promoter region of a target gene. 
[72]
 This is followed by the 
recruitment of coactivator complexes, which then mediate enzymatic reactions, remodeling the 
chromatin and facilitating the association of the RNA polymerase II complex with the general 
transcriptional machinery at the target gene promoter. Because coregulators impact the 
transcriptional activity of multiple NRs and other types of transcription factors, they exert broad 
genome-wide effects on genetic networks and contribute significantly to a large spectrum of 
physiological abnormalities and diseases (Figure 15).
[73]
 
 
Figure 1.5: Nuclear receptor coactivators control the physiology of multiple organs that are critical 
for various metabolic disorders and some rare genetic diseases as well. Target genes 
transcriptionally regulated by the coactivators that indicated in red. Adapted from Dasgupta et.al 
[73]
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SRC family of the three members (SRC-1, SRC-2, and SRC-3) of the p160 class of coactivators 
have been widely implicated in the regulation of steroid hormone action by mediating functions of a 
majority of the NRs and transcription factors, and their abnormal expression in different 
malignancies and genetic diseases has distinguished them as master regulators of human 
pathologies
[74] 
(Figure 1.6). Peroxisome proliferator-activated receptor gamma, coactivator 1 alpha 
(PGC-1α) is another important coactivator that involved in the regulation of metabolism and energy 
homeostasis. Expression levels of PGC-1α in various tissues have been associated with genetic 
predispositions to diseases with impaired mitochondrial function, including type 2 diabetes mellitus 
and obesity.
[75]
 Other coactivators, such as CREB-binding protein (CBP)-p300, interact with 
virtually all transcription factors and regulate gene expression by relaxing chromatin structure at the 
target gene promoter through their intrinsic histone acetyltransferase (HAT) activity. In addition to 
chromatin remodeling, coactivator-associated arginine methyltransferases (CARM1/PRMT4) also 
stimulate gene transcription by activation of NRs and other transcription factors in combination 
with the SRC family of coactivators.
[73]
 
 
Figure 1.6: Steroid receptor coactivators (SRC family members) are abundantly expressed and 
amplified in various forms of cancer. Adapted from Dasgupta et.al 
[73]
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NR coactivators are unable to bind directly to the DNA. Instead they form multiple contacts with 
the NR and with each other in multi-protein cooperative coactivator complexes. Initial 
investigations into coactivator complexes reported that steady-state SRC complexes consist of six 
to ten stably associated proteins and many more loosely-bound proteins.
[76]
 
SRCs contain three structural domains. The N-terminal basic helix-loop-helix-Per/ARNT/Sim 
(bHLH-PAS) domain is the most conserved region and is required for protein-protein interactions. 
The bHLH-PAS domain can interact with several transcription factors such as myogenin, MEF-2C 
and TEF to potentiate transcription. The central region contains three LXXLL (L for leucine and 
X for any amino acid) motifs, which form amphipathic α-helices and are responsible for 
interacting with NRs. The C-terminus contains two transcriptional activation domains (AD1 and 
AD2). AD1 binds CBP (CREB (cAMP response element-binding protein)) and p300 histone 
acetyltransferase (HAT), and the recruitment of CBP or p300 by SRCs to the chromatin context is 
essential for SRC-mediated transcriptional activation. AD2 interacts with coactivator-associated 
arginine methyltransferase 1 (CARM1) and protein arginine methyltransferases (PRMT1), which 
are histone methyltransferases. The C-termini of SRC-1 and SRC-3 contain HAT activity 
domains, although their cellular substrates are incompletely identified. These molecular features 
provide SRCs with a suitable structural base for recruiting additional coregulators and general 
transcription factors, which in turn results in chromatin remodeling, assembly of general 
transcription factors and recruitment of RNA Polymerase II for transcriptional activation. The 
basic SRC structural domains and the simplified functional mechanisms for SRCs in NR-
dependent transcriptional activation are sketched in (Figure1.7).
[77]
 To exert their coactivation 
function in transcription, SRC interact with hormone (H)-bound nuclear receptors (NRs) to recruit 
other components of a large coactivator complex to the hormone response elements of a target 
gene. Specifically, SRCs bind NRs through one of their three LXXLL motifs (L1, L2 and L3) in 
the NR interaction domain (NRID) and interact with CBP and p300 through their activation 
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domain 1 (AD1), with CARM1 and PRMT1 through their AD2 and with SWI/SNF through AD3. 
p/CAF is a p300/CBP-associated factor. CBP, p300 and p/CAF are histone acetyltransferases. 
CARM1 and PRMT1 are histone methyltransferases. RHA is a RNA helicase. SWI/SNF is an 
ATP-dependent chromatin remodeling complex. The formation of such a coactivator complex 
results in chromatin remodeling and bridges the hormone-activated NRs with the general 
transcription machinery for transcriptional activation of their specific target genes.
[77]
 
 
Figure 1.7: Molecular structure of SRCs and their functional mechanisms in steroid hormone-
induced gene expression .Adapted from Normal and cancer-related functions of the p160 steroid 
receptor co-activator (SRC) family (Xu et.al, 2009). 
[77]
 
 
1.5.3. Conformational changes in NRs ligand binding domaine (LBD) 
Ligand binding domain (LBD) adopts a three-layer antiparallel α-helical sandwich fold, consisting 
of 12 α-helices with a ligand-binding pocket. The hydrophobic AF-2 surface (helix 3/4/5/12 
interface) provides a binding site for coactivator proteins with an LXXLL recognition motif.
[78]
 
Conformational changes happen in the LBD upon binding agonists, antagonists, or partial 
agonists. These conformational changes vary depending on which particular type of molecule is 
bound and govern the nuclear receptor’s ability or inability to activate gene transcription. The 
most striking difference in the conformation of the LBD structures is the orientation of helix H12, 
which contains the residues of the AF-2 activation domain core. In the apo or unliganded 
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conformation (Figure1.8 (a)), helix 12 is generally thought to be extended away from the LBD.
[79]
 
Upon agonist ligands binding, this helix rotates nearly 180 to pack tightly against the LBP, 
serving as a lid closing the entrance to the LBP (Figure1.8(b)). This brings the AF-2 into position 
to generate a surface for binding of coactivators that are necessary for nuclear receptor gene 
transcription activation. 
[55]
  
 
Figure 1.8: Ligand binding to NRs results in a conformational change in the protein. (a) apo 
conformation, (b) agonist conformation, (c) antagonist conformation, (d) partial conformation. 
Adapted from Nuclear Hormone Receptors: A Brief Overview J.P. Vanden Heuvel, INDIGO 
Biosciences Inc., State College PA. (Heuve, 2009)
[41]
 
    
Antagonist binding inhibits gene transcription. Unlike agonists, they have bulky side chains that 
cannot be accommodated within the agonist binding cavity. This bulky side chains sterically 
prevent the positioning of helix H12 in the active conformation and no coactivator interface is 
formed (Figure 1.8 (c)). The antagonists also induce unwinding of the C-terminal part of helix 
H11. This allows helix H12 to bind to the coactivator binding region, therefore blocking 
coactivator binding. In contrast, agonists stabilize the long H11 helical conformation.
[80]
 Pure 
antagonists differ from partial agonists based largely in their steric properties. Partial agonists do 
not contain a bulky extension, so they do not sterically preclude the agonist position of H12 
(Figure1.8 (d)). In this respect, they are more like agonists. However, these molecules do induce 
unwinding of helix H11 and in this respect are similar to antagonists. The partial activity of the 
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ligand in this case is attributed to a weak stabilization of the active position of H12, so the active 
conformation of the LBDs is not stabilized. The position of H12 in this case probably depends on 
the intracellular concentration of co-activators and co-repressors.
[55]
 These ligand-bound 
structural observations have been used as a model to understand the mechanism of action of 
ligands and are generally used as a guide for nuclear receptor virtual ligand screening and 
structure-based drug design efforts. 
Of all the surfaces available on a given NR, the singular site for regulation of receptor activity 
has almost invariably been the ligand-binding pocket of the receptor, the site where agonists, 
antagonists, and selective NR modulators interact. With the increasing understanding of the 
multiple molecular components involved in NR action, researchers have recently begun to look 
to additional interaction sites on NRs for regulating their activities by novel mechanisms. The 
alternate NR-associated interaction sites that have been targeted include the coactivator-binding 
groove and allosteric sites in the ligand-binding domain, the zinc fingers of the DNA-binding 
domain, and the NR response element in DNA. 
[81]
 Phenotypic and conformation-based screens 
have also identified small molecule modulators that are believed to function through the NRs and 
act as direct protein/ protein disruptors of the interaction between the nuclear receptor (NR) 
ligand binding domain (LBD) and the receptor coactivators. These compounds were termed as 
coactivator binding inhibitors or (CBIs).
[82]
 CBIs have been discovered for the estrogen receptor 
(ER), thyroid receptor (TR), androgen receptor (AR), and the peroxisome proliferator activated 
receptor (PPAR). 
[83]
 
1.5.4. Estrogen Receptor and its Role in breast Cancer Biology 
The estrogen receptor (ER), a member of the superfamily of ligand-regulated nuclear transcription 
factors, mediates the action of estrogens, including the primary endogenous ligand 17β-estradiol 
(E2) (Figure 1.9) (a).
[84]
 ERs exist as two subtypes, ERα and ERβ, and because they are found in 
both reproductive (uterus, ovary, and breast) and non-reproductive (bone, brain, and the 
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cardiovascular system) tissues, they have emerged as attractive therapeutic targets for the 
treatment of breast cancer, the prevention of osteoporosis, and the mitigation of menopausal 
symptoms via hormone replacement.
[85]
 The genes of ERα and ERβ also differ in their location in 
the genome, as the former resides on chromosome 6 and the latter on chromosome 14. (Figure 
1.9) (b) Shows the genomic composition of ER subtypes. 
 
Figure 1.9: (a) Estradiol (E2) structure, (b) the genomic composition of ER subtypes. Adapted 
from Pearce et al.
 [86]
 
 
In contrast to the widely acknowledged paradigms involving chemicals and viruses as tumor 
initiators and promoters, the hormone-related cancers, such as breast cancer, share a quite different 
mechanism of carcinogenesis. Hormones, both endogenous and exogenous, by driving cell 
proliferation, increase the number of cell divisions and the opportunity for random genetic errors.  
Based on data from both clinical and animal studies, risk factors associated with breast cancer 
reflect cumulative exposure of the breast epithelium to estrogens. Estrogens are implicated in the 
development of breast cancer, which induce physiological activities mainly via estrogen receptors 
(ERs).
[87]
 
Clinical observations and laboratory studies suggest that ER signaling pathway is the major driver 
in promoting proliferation, survival and invasion of ER-positive breast cancer cells.
[88]
The 
expression level of ERα is high and have been directly correlated with an increased risk of breast 
cancer while it is low in normal breast tissue.
[89]
 Endocrine therapy is the mainstay of treatment for 
patients with ER-positive breast cancer, especially those with metastatic disease. These therapies 
include treatments which target ER by blocking receptor binding with an antagonist or by depriving 
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the tumor of estrogen. The three broad groups of currently approved anti-estrogen therapies are 
selective estrogen receptor modulators (SERMs) such as tamoxifen (58), toremifene (59) and 
raloxifene (60), which block activity of ER and functions as estrogen antagonist in breast cancer 
cells, but it also functions as an agonist in some tissues including the bone, uterus, liver, and the 
cardiovascular system; selective estrogen receptor down regulators (SERDs) such as fulvestrant 
(ICI 182, 780)  (61), which induce destabilization and degradation of ER; 
[90]
 and aromatase 
inhibitors (AIs), including steroidal/irreversible (anastrozole (62) and letrozole (63)) and 
nonsteroidal/reversible (exemestane (64)) inhibitors (Figure 1.10), which decrease estrogen 
production in peripheral tissues and within the tumors through inhibition of the enzyme 
aromatase.
[91]  
Endocrine therapy as the first targeted therapy in cancer treatment has successfully 
improved outcomes and was beneficial to millions of breast cancer patients in the past 30 years. 
Nonetheless, finding ways to inhibit ER activation is necessary and is hoped to maximize treatment 
opportunities in breast cancer treatment 
[92]
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Figure 1.10: anti-estrogen compounds. Tamoxifen (58), toremifene (59) and raloxifene (60), 
fulvestrant (61), anastrozole (62), letrozole (63), and exemestane (64). 
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Tamoxifen is the most commonly used treatment for patients with estrogen-receptor (ER)-positive 
breast cancer as a part of adjuvant chemo-endocrine therapy.
[93] 
Although many patients get benefits 
from tamoxifen in the adjuvant and metastatic settings, resistance is an important clinical problem. 
Such mechanisms may include changes in the expression of ERα or ERβ, alterations in co-
regulatory proteins, and the influences of cellular kinase signal transduction pathways.
[94] 
Several different mechanisms have been hypothesized to be involved in the resistance of breast 
cancer cells to hormonal therapy (Table 1.4).  About 20% of patients treated with endocrine therapy 
suffering from ER loss in the tumor over time. Such tumors would no longer be driven by estrogen, 
but the escape pathways which take over with loss of estrogen dependence still not well defined. Up 
regulation of HER2 (Human Epidermal Growth Factor Receptor Type 2) by either acquisition of 
gene amplification or overexpression that occur in some tumors. HER2 may subsequently assume 
the driving role in tumor progression by serving as an alternative survival pathway or by reducing 
the level of ER, thus rendering the tumor less responsive to estrogen. Preclinical and clinical data 
suggest the possibility that tumors can alternate between ER and HER2 as the dominant pathway, 
with targeted therapy against one pathway causing reactivation of the other. On the other hand, PR 
is lost more frequently than ER with intervening endocrine therapy and with this loss the tumor 
becomes more aggressive and patients have a worse survival outcome than patients who maintain 
PR expression after resistance to one endocrine therapy. In this case, PR loss might be associated 
with increased growth factor signaling and upregulation of the PI3K pathway, which downregulates 
PR and ER expression. [95],[96],[97] 
Table 1.4: Potential mechanisms of resistance to endocrine therapy in breast carcinoma. 
 
Loss of expression or altered function (mutations) of ERα 
Upregulation of HER2 in some patients after endocrine therapy 
Loss of PR after progression on endocrine therapy 
Metabolism of hormonal agents (CYP2D6 variants for tamoxifen) 
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Altered expression of co-regulators 
Adaptation to estrogen withdrawal 
Shorter response duration and less frequent responses with sequential endocrine 
therapies 
Increased growth factor signaling 
Eventual loss of dependence on estrogen with resistance to all endocrine therapies 
 
 
ER has two sites that are prone to be affected by drugs - the Ligand Binding Domain (LBD) in 
which the natural agonist, Estradiol (E2) resides and affects movement to the cell's nucleus for 
transcription, and the Coactivator Binding Domain (CBD) which is activated by the binding of E2, 
where proteins of the Steroid-Receptor-Coactivator family (SRC-1,2 and 3) bind to ER and help 
lead it to the nucleus and transcription promotion.  
1.5.5. Coactivator Binding Inhibitors (CBIs) of estrogen receptor ER 
 
Traditionally, the inhibition of ER activity has been achieved using antagonist molecules that bind 
to the ligand binding pocket in place of estradiol and trigger a conformational change that indirectly 
blocks coactivator binding by an intra-receptor or allosteric process.
[98]
An alternative and yet 
underexploited approach to blocking estrogen action involves small molecules that disrupt the 
interaction between agonist-activated ER and the SRC by an extra-receptor or direct competitive 
process. Such molecules are termed coactivator binding inhibitors (CBIs). (Figure 1.11 (I)).
[99] 
Compounds termed as coactivator binding inhibitors (CBIs) designed to bind only to the coactivator 
binding surface of ER by fitting directly into the coactivator binding groove on the surface of the 
ligand binding domain LBD. Thus, block coactivator recruitment to the estrogen receptor ligand 
binding domain LBD.
[100] [100]
 The steroid receptor coactivators (SRCs), possess multiple copies of a 
conserved signature sequence motif, LXXLL (L is leucine and X is any amino acid), known as a 
nuclear-receptor interaction box (NR-box). The coactivators bind to the nuclear receptor LBD 
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through a two-turn amphipathic α-helical motif encompassing the NR box LXXLL signature 
sequence, with the ER-coactivator complex being further stabilized by interactions between the 
intrinsic dipole moment of the helical coactivator peptide backbone and charged residues (the 
glutamic acid and the lysine) from the ER at either end of the binding groove. The X-ray structure 
of the ERα complex with the NR box of SRC shows this interaction in detail (Figure 1.11 (II)).[101]  
Among the key interactions of the ILXXLL sequence are the hydrophobic contacts of the sidechains 
of the leucine and isoleucine residues with the hydrophobic coactivator binding surface of ER. The 
isoamyl sidechains of two leucines (ILXXLL) are pointed down towards ER into a deep 
hydrophobic groove. The side chains of the isoleucine and another leucine (ILXXLL) are sitting on 
a "shelf above the groove and form a weaker, but essential hydrophobic interaction. 
[102]
 The peptide 
is amphipathic, and the hydrophobic residues on one face of the helix are favorably disposed to 
project into a non-polar groove on the receptor while the polar side chains of the XX residues, are 
on the opposite face of the helix are exposed to and can hydrogen bond with water. Also, the 
inherent dipole of the a-helical peptide orients the NR Box sequence in one direction. A "charge 
clamp" is present through which a lysine and a glutamic acid on the ER surface can interact 
favorably with the negative and positive ends, respectively, of the inherent dipole of the helical 
peptide. 
[103]
 
 
Figure 1.11: (I) electrostatic surface of the estrogen receptor with the coactivator peptide (red 
tube). (II) Cartoon representation of classical vs. CBI antagonism of ER. (A) Conformation of 
agonist-bound ER with helix 12 forming part of the steroid receptor coactivator (SRC) binding site; 
(B). Conformation of antagonist-bound ER in which helix 12 occupies the SRC binding site, 
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disrupting the ER/SRC interaction indirectly; (C) conformation of agonist-bound ER in which a 
CBI occupies the SRC binding site, disrupting ER/SRC interaction directly. Adapted from (Parent, 
2008 ) 
[104]
.
  
 
1.5.6. Literature Reviews 
 
Although it is a recently developed area of research, some CBIs have already been discovered to 
inhibit ERα -coactivator association. In 2003 Leduc et al. created one of the first successful CBIs by 
mimicking the LXXLL coactivator peptide. They found it was necessary to keep the α-helical 
character so that the hydrophobic side chains could interact with the pocket, and the two XX 
hydrophilic residues would face away from the surface as in the natural peptide. After considering 
these elements, PERM-1, synthesized by Leduc et al. showed the best results. This molecule 
contained a disulfide bridge, to maintain the desired α- helical shape (Figure 1.12 (a)). Using a 
time-resolved fluorescence-based coactivator interaction assay, they were able to observe some 
selectivity as PERM-1 gave a Ki of 25 nM and 390 nM, for ERα and ERβ respectively. They were 
also able to confirm that PERM-1 was binding to the correct site based on an X-ray crystal structure 
of ER with estradiol and PERM-1.
[105]
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Figure 1.12: (a) PERM-1 by Leduc et al.
 [105]
 (b)(c) Small molecule CBIs from Shao et al.
 [106]
, 
(d) guanylhydrazone-based CBI by Andrew L. LaFrate et al..
 [107]
 
 
Shao et al. (2004) took a different approach in the development of a good small molecule ER 
coactivator inhibitors based on the guanylhydrazone structure. By examining libraries of small 
molecules via a high-throughput screening (HTS) and virtual screening (VS) for their ability to act 
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as ERα antagonists. Two successful CBIs were identified, ERI-5 (Figure 1.12 (b)) was the first hit 
discovered by HTS that gave an IC50 of 5.5 μM in a mammalian two hybrid (M2H) assay, where 
both estradiol and ERα antagonist (fulvestrant) ICI182,780  (61) (Figure 1.10)  are present along 
with steroid receptor coactivator-3 (SRC-3) and human ERα. Further biological testing of ERI-5, in 
a non cell-based interaction assay containing only SRC and ERα (SEIA), showed that it inhibits 
ERα-coactivator association. ERI-5 also demonstrated inhibition activity for ERβ. The second small 
molecule, ERI-7 (Figure 1.12 (c)) was identified by virtual screening on diethylstilbestrol-bound 
ERα co-crystallized with an LXXLL peptide. Because it was not as cell-permeable as ERI-5, ERI-7 
was tested only in the SEIA assay, and displayed an IC50 of 25 μM. Both CBIs were assessed in a 
competition assay, where it was concluded that they did not displace E2 and were not directly 
competing with estradiol, but still blocked ERα activity. An NMR assay of ERI-5 and ERI-7  bound 
to ERα protein showed levels of free estrogen that did not increase when more ERI-5 and ERI-7 
was added, meaning there was no estradiol displacement ERI-5 and ERI-7 bound elsewhere on 
ERα. [106]  
Andrew L. LaFrate and his colleagues at the University of Illinois Urbana-Champaign expanded 
upon this work by designing a synthetic route to these guanylhyrazone-based molecules, starting 
from α-tetralone.[107] They synthesized a series of 16 potential CBIs and subjected them to 
mammalian two-hybrid assays and cell-based reporter gene assays to determine their potency for 
ERα. These studies demonstrated that the compounds do not compete directly with E2 at the LBP. 
The compound JAK-28 in (Figure 1.12 (d)) exhibited the best results with an IC50 of 0.9 μM in the 
cell based reporter gene assay showing that the phenyl group and chlorine are important to binding 
and that an acyclic middle portion is preferred. Substitutions on the ring proved to be unfavorable. 
This class of CBIs is interesting because they do not represent the typical α-helical mimic 
properties, but clearly can adopt of the proper configuration for inhibiting co-activator proteins.
  [107]
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In 2007 the Katzenellenbogen group has also published a study of ERα CBIs that based on a 
bicyclo[2.2.2]octane. This time they took what they referred to as an “inside-out” approach in 
which they mimicked the first and third leucine residues of the NR box that extend “inside” the 
CBP. They then attached structural elements that represent the backbone of the coactivator α-helix 
which is “out” of the pocket. Using molecular modeling it was determined that a boat cyclohexane 
ring would replicate the alignment of the two isopropyl groups. Two atoms on one of the leucines 
create a 1,4-bridge which led to the bicyclo[2.2.2]octane core, which can be further functionalized 
to mimic the third leucine residue or the helical backbone.
[108]
 These compounds were evaluated 
using time-resolved fluorescence energy transfer (TRFRET) assays to evaluate their ability to 
compete with the SRC3 co-activator for the ERα. The results showed that these compounds were 
modest CBIs with Ki values in the range of 7-40 μM. The best CBI is shown in (Figure 1.13 (a)). 
This is promising because these bicyclo[2.2.2]octanes are actually incomplete helical mimetics. Due 
to synthetic difficulties of adding an additional amide group, these compounds only mimic one of 
the leucine residues and the compounds still bind in the low micromolar range. 
In 2009 a series of bipolar biphenyl proteomimetic compounds was designed and synthesized by 
Williams et.al as estrogen receptor-α (ERα) coactivator binding inhibitors, based on a bipolar bis-
4,4'-oxyphenyl scaffold that addresses both the substitution pattern of the hydrophobic core and the 
electronic interactions of the charge clamp. Each compound in the series contains a tertiary amine 
and a carboxylic acid connected by an ether linkage to the biphenyl core. The compound shown in 
(Figure 1.13 (b)) exhibits a Ki of 33 μM and presents as the most promising candidate for follow-
up medicinal chemistry in that series. These compounds were subjected to cotransfection reporter 
gene assays in human endometrial cancer (HEC-1) cells, which express nuclear receptor 
coactivators but contain no endogenous ERα. The compound in (Figure 1.13 (b)) shows evidence 
of inhibitory activity, with an IC50 of ~2 μM but only limited inhibitory efficacy.
[109]
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Figure 1.13: (a) Cyclohexane connector (purple) creates a bicyclo[2.2.2]-octane CBI core from 
L690 and L694 of an SRC NR box peptide. (b) biphenyl proteomimetic compound with tertiary 
amine and a carboxylic acid connected to the biphenyl core. (c) pyridylpyridone based ERα CBIs. 
 
 
Hamilton’s group has also described a small set of pyridylpyridone based ERα CBIs. These are 
modified versions of their terphenyl Bcl-xL/Bak inhibitors discussed earlier. This trisubstituted 
scaffold also has three hydrophobic groups that can project into the CBP. The molecule in (Figure 
1.13 (c)) showed the ability to disrupt ERα/co-activator activity in a fluorescent polarization assay 
based on rhodamine-labeled peptide D22 which contains a single LXXLL motif with IC50 value 4.2 
μM.[102]  
Another class of compounds that inhibit the ERα/co-activator interaction is based on a pyrimidine 
core was prepared in 2004. Rodriguez et al. had described an approach to developing small 
molecule coactivator binding inhibitors (CBI) by a de novo, structure-inspired approach, and 
evaluated a set of candidate CBIs for their activity in blocking the binding of a model nuclear 
receptor interaction box (NR box) peptide. They took two structure-based approaches where they 
considered the interactions of the three leucines in the LXXLL motif as an essential requirement for 
their CBIs based on the concept that the three leucine residues roughly adopt a triangular formation. 
Basing their search on the crystal structure of LXXLL, they found two sets of molecules (Class I (a) 
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and Class II (b) (Figure 1.14)) that could potentially have coactivator binding activity. The first set 
of CBIs (Class I), based on an outside-in design approach, has various heterocyclic cores (triazenes, 
pyrimidines, trithianes, cyclohexanes) that mimic the tether sites of the three leucines on the peptide 
helix. Hydrophobic substituents were then placed in alternate positions around the heterocyclic 
rings to mimic the leucine residues, and in some cases, polar functionalities were added to interact 
with the charge clamp residues in the ER LBD. The other set Class II, based on an inside-out 
approach, has a naphthalene core that mimics the two most deeply buried leucines, with substituents 
extending outward to mimic other features of the coactivator helical peptide. A fluorescence 
anisotropy-based coactivator competition assay was developed to measure the specific binding of 
these CBIs to the groove site on the ER-agonist complex with which coactivators interact by 
measuring the displacement of a fluorescent labelled octapeptide containing one (NR box) by each 
CBI; control ligand-binding assays assured that their interaction was not with the ligand binding 
pocket.
[19]
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Figure 1.14: Class I (a), Class II (b) type molecules using two different approaches; (c) the best 
pyrimidine based ER CBI (12a). Adapted from Rodriguez et al.
[19]
 
 
After testing triazene, pyrimidine, trithiane, and cyclohexane from Class I. Pryimidine cores proved 
to be the most successful ERα inhibitors with a trialkyl-substituted compound 12a (Figure 1.14 (c)) 
giving a Ki of 29 μM, the two alkyl substitutuents of CBI 12a projecting downward into the deep 
hydrophobic groove of the receptor, filling the area normally occupied by L690 and L694. The third 
alkyl substituent sits comfortably on the hydrophobic shelf occupied by I689 in the ERR crystal 
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structure. The interaction between pyrimidine 12a and the receptor appears to be entirely 
hydrophobic in nature, as indicated by the lack of hydrogen bonding or electrostatic interactions in 
this model (Figure 1.15). To determine whether their best CBI was in fact inhibiting by displacing 
the coactivator peptide, they measured its relative binding affinity in a radiometric assay with 
estradiol and ER LBD and obtained a 0.01% RBA of E2. Hence, as with previous examples, the 
trialkyl-subsituted pyrimidine was not binding to the LBD but to the ER-coactivator surface as they 
hoped.
[19]
  
 
Figure 1.15: pyrimidine CBIs (12a) mimicked the leucine side chains with three isobutyl arms. 
Adapted from Rodriguez et al.
[19] 
In 2008, Parent et al. synthesized a larger library of pyrimidine CBIs based on previous successful 
of trialkyl-subsituted pyrimidine CBI. A pyrimidine-core library of moderate size, members of 
which act as α-helix mimics to block ERα/coactivator interaction had been synthesized. Structure- 
activity relationships had been explored with various C, N, O and S-substituents on the pyrimidine 
core. Through those studies, a refined pharmacophore model for activity in this pyrimidine series 
had been obtained. The library of 68 trisubstituted pyrimidines were synthesized and the potency of 
compounds as inhibitors of the interaction of ERα and ERβ with SRC-3 was characterized using a 
time-resolved fluorescence resonance energy transfer assay (TR-FRET) and a cell-based E2-induced 
reporter gene assay in human cancer cell lines. (Figure 1. 16) shows a small subset of the Parent 
library and their binding affinities. They successfully found a far more potent CBI, K-11c, which 
gave the lowest binding affinity, Ki of 1.7 μM. Furthermore, the favorable activities of several of 
these compounds support the feasibility that this coactivator binding inhibition mechanism for 
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blocking estrogen action might provide a potential alternative approach to endocrine therapy. As 
before, they identified the type of inhibition of their active pyrimidine CBIs in an in vitro 
competitive radiometric assay with tritium-labeled estradiol as a tracer and full-length purified 
human ERα and Erβ. The relative binding affinities of their molecules ranged from 0.005 to 0.051% 
of E2. Their molecules were indeed inhibiting coactivator association and not through the classical 
displacement of E2.
[104]
 
 
Figure 1.16: A small subset of Parent's pyrimidine CBI library and their biological activities.
[104]
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1.5.7. Pyrimidines as a Coactivator Binding Inhibitors (CBIs) of Androgen Receptor (AR) 
The androgen receptor (AR) is a member of the nuclear hormone receptor superfamily and plays an 
integral role in primary and secondary sexual development in males. While abnormalities resulting 
in an attenuation of the AR response to endogenous hormones (testosterone and its reduced form, 5-
dihydrotestosterone or DHT) produce male infertility and feminization, excessive stimulation of the 
AR can also result in pathologies. The most commonly presented diseases of this type are prostate 
cancer and the related but benign prostatic hyperplasia. Both of these diseases are responsive to 
endocrine-based treatments that attempt to suppress tumor/prostate growth either by direct 
administration of an AR antagonist or by “chemical castration” techniques that result in decreased 
gonadal production of the endogenous agonist, testosterone.
[110]
 Traditional AR antagonists, such as 
flutamide or bicalutamide, act by binding to the ligand binding pocket of the receptor, resulting in a 
conformational change of the ligand binding domain (LBD) such that helix 12 occludes the binding 
of coactivators that are required to activate transcription. Consequently, this type of inhibition can 
be considered a type of indirect or allosteric modulation of AR activity, because inhibitor binding in 
the ligand-binding pocket is disabling a protein_protein interaction at a separate site. While 
treatment with traditional AR antagonists is initially met with suppression of prostate tumor growth, 
with time (a few months to years), cellular modifications including AR mutations, upregulation of 
AR and coactivators, changes in the post-translational modification of AR and accessory proteins, 
as well as increased androgen production by the suprarenal glands and in the tumors themselves, 
result in a endocrine-treatment refractory state in which cancer progression occurs despite the 
presence of an antagonist. As a result, new chemical approaches need to be developed to 
successfully treat this advanced-stage disease. 
[111],[112]
 
Katzenellenbogen et al. and others have recently described the evaluation of small CBIs molecules 
that act as direct protein/ protein disruptors of the interaction between the estrogen receptor (ER) 
LBD and steroid receptor coactivators (SRCs). Due to the general homology of the external binding 
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groove of the LBDs of both ER and AR, as shown in crystallographic studies, and the sharing of 
coactivators containing the LXXLL consensus sequence.
[113]
 Jillian R. Gunther et .al hypothesized 
that compounds containing structural characteristics similar to those that proved effective as ER 
CBIs would also antagonize the AR/SRC interaction. Additionally, the ability of the AR LBD to 
bind preferentially to coregulator proteins and peptides containing bulkier aromatic residues 
suggested that AR-selective CBIs could be formed by simple incorporation of larger side chains on 
already discovered CBI cores. To test this hypothesis, they designed a compound library based on a 
2,4,6-trisubstituted pyrimidine core that had proven effective in earlier ER-CBI work and was 
designed to mimic the i, i + 3, and i + 4 arrangement of the three interacting residues of both the ER 
and AR coactivators (Figure 1.17). In addition to the smaller propyl/butyl and isobutyl/ isopentyl 
groups previously studied, they included larger benzyl/phenethyl and naphthalenemethyl/ 
naphthethyl moieties in their design to mimic the phenylalanine and tryptophan residues present in 
the endogenous AR transcriptional system. A structure-based peptidomimetic approach was used to 
design and synthesize compounds that directly disrupt the androgen receptor/steroid receptor 
coactivator interaction and function as novel inhibitors of androgen signaling that would remain 
effective in the treatment of prostate cancer that is resistant to conventional endocrine therapies, 
based on a pyrimidine-core system. Using fluorescence resonance energy transfer and reporter gene 
assays, Jillian R. Gunther et .al identified members of this library that disrupt the androgen 
receptor/steroid receptor coactivator interaction selectively, without affecting the estrogen 
receptor/steroid receptor coactivator interaction. Unlike the activity of traditional androgen receptor 
antagonists, such as flutamide and bicalutamide, inhibition by these coactivator binding inhibitors is 
insurmountable by increased concentrations of androgen agonists and maintains effectiveness even 
on a mutant androgen receptor that is resistant to traditional antagonists. These findings support the 
feasibility of targeting the coactivator binding groove of the androgen receptor as an alternative 
approach to treatment-resistant prostate cancer therapy.
[114]
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Figure 1.17: A small subset of Jillian R. Gunther et .al pyrimidine CBI library and their biological 
activities. 
 
Some initial docking studies were done on Katzellenbogen et al. best CBI using FlexiDock with the 
SYBYL platform to obtain a clearer picture of the binding mode to ERα. Using the crystal structure 
of GRIP-1 peptide and overlapping the interactions, they determined that the three alkyl chains of 
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their CBI were occupying the two deep pockets. However, it was lacking the capping interactions of 
the peptide with the two polar residues of the charge clamp. In fact, in their study, Lys362 clearly 
makes an H-bond interaction with the coactivator peptide, but is slightly shifted to the left with their 
best CBI. It was therefore concluded that no polar or H-bond interactions were involved in the 
binding modes but simply hydrophobic interactions were made with their CBI and Erα. Lastly, their 
docking analysis suggested that the ER-coactivator surface is flexible and therefore should be 
capable of accommodating various sizes of CBIs for future design purposes.
[19]
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Aims and Objectives of the Study: 
The major objective of this study was to explore the possibility to design and prepare a small 
molecule pyrimidine-based coactivator binding inhibitors (CBIs) that mimic the NR interaction 
domain containing multiple LXXLL (here L represents leucine and X represents any amino acid ) 
motifs which plays crucial role in the interaction of the NR with steroid receptor coactivator 
(SRC). CBIs are believed to interrupt the Estrogen Receptor activity by interfering with the 
interaction of NR-ERα with coregulators (SRC-1, -2, and -3). 
 
Specific Goals of the Study: 
1. Design, synthesis, purification, and characterization of series of novel 2,4-disubstitited 
pyrimidienes.  
2. Design, synthesis, purification, and characterization of series 2,4,6-trisubstituted pyrimidine 
derivatives. 
3. Development of appropriate synthetic methods to prepare hetero-trisubstituted pyrimidine-
cored derivatives. 
4. Assessment of the biological activity of  newly 2,4-disubstitited pyrimidines as Acute Myeloid 
Leukemia (AML) growth inhibitors. 
5. Investigate the Structure Activity Relationship (SAR) of the 2,4-disubstitited pyrimidines. 
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Chapter 2 
 
Experiments and Methods 
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2. Experiments and Methods 
2.1. Synthetic Chemistry: 
2.1.1. Materials: 
Chemicals: 2,4,6-trichloropyrimidine (1), 4-fluoroaniline (2), 4-trifluoromethoxyaniline  (3), BOC-
piperazine (4), 1-(5-trifluoromethylpyridin-2-yl)-piperazine (5), 1-(3-trifluoromethyl-pyridin-2-yl)-
piperazine (6), N-phenylpiperazine (7), 2-(1-piperazinyl)pyrimidine (8), 1-(4-pyridyl)piperazine (9), 
3,4-dimethoxybenzoic (10), benzoyl chloride (11), ethanolamine (12), sodium sulfate (Na2SO4), 
potassium carbonate (K2CO3), diisopropylethylamine (DIPEA), dichloromethane (DCM), ethyl 
acetate (EtOAc), dioxane, hexane, isopropanol, chloroform (CHCl3), tert-butanol, triethylamine 
(TEA), hydrochloric acid (HCl) ethanol (EtOH), hexane, isopropanol, dichloromethan (DCM), 
chloroform (CHCl3) and hydrochloric acid (HCl) were purchased from ACROS Chemicals Ltd, and 
were used without further purification.  
Silica gel (Silica gel 60 (0.040-0.063 mm)), thin layer chromatography (TLC) (TLC Silica gel 60 
F254) sheets were all purchased from Merck Ltd.  
Deuterated solvents: D2O, CDCl3, DMSO-d6 were purchased from ACROS Chemicals Ltd. 
2.1.2. Instrumentation:  
2.1.2.1. Nuclear magnetic resonance (1H-, 13C-, NMR): 
Data were collected using Varian Unity Inova 300 MHz spectrometer equipped with a 5-mm 
switchable probe and data were processed using the VNMR software. 
1
H-NMR chemical shifts are 
reported in parts per million (ppm, δ) downfield from tetramethylsilane (TMS). Spin multiplicities 
are described as s (singlet), d (douplet), t (triplet), q (quartet), and m (multiplet).  
2.1.2.2. Fourier transform infrared spectroscopy (FTIR): 
 All infrared spectra were obtained from a KBr matrix (4000–400 cm-1) using a Perkin-Elmer 
spectrum 100, FT-IR spectrometer.  
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2.1.2.3. Electrospray ionization mass spectrometry (MS (ESI)): 
Was performed using a Thermo Quest Finnigan LCQ-Duo in the positive ion mode. Elution was in 
a mixture of 49:49:2 water/methanol/acetic acid at a flow rate of 15 μL/minute. 
2.1.3. Synthesis of (4-amino-2,6-dichloropyrimidine) derivatives (15-21) 
In a 25 ml round bottom flask 2,4,6-trichloropyrimidine (1) (1g, 5.45 mmol)  was dissolved in 
dioxane (15 ml). To the mixture the relevant aromatic or aliphatic amine (1.1 mmol) and DIPEA 
(diisopropylethylamine) (1.2 mmol) were added at room temperature. While stirred, the mixture 
was heated at reflux for 8–12 hour until completion of the reaction. The reaction progress was 
followed using TLC. After the reaction completion volatiles were removed under reduced pressure 
using rotary evaporator. The residue was extracted using ethyl acetate and water (30ml X 3). The 
organic fractions were pooled and dried using sodium sulfate (Na2SO4). Ethyl acetate was removed 
under reduced pressure to dryness. The crude material was purified by silica gel column 
chromatography using CHCl3: hexane (40:60; v: v) as eluent to give the 4-amino-2,6-dichloro 
pyrimidines in 40-70% yield. 
2.1.3.1. Synthesis of (2,6-dichloropyrimidin-4-yl)-(4-fluorophenyl)-amine {M1 (15)}: 
TLC (CHCl3: hexane (70:30; v: v)), Rf =2.1/5.3=0.39; light brownish powder; yield: 0.9 g (64%);
 
1
H-NMR 300 MHz (DMSO) δ (ppm): 10.25 (s, 1H), 7.51(d, 2H), 7.18 (d, 2H), 6.68 (s, 1H). 
2.1.3.2. Synthesis of 4-(2,6-dichloropyrimidin-4-yl)-piperazine-1-carboxylic acid tert-butyl 
ester  {M2 (16)}:  
TLC (CHCl3: hexane (80:20; v: v)), Rf =3.5/6.2=0.51; light gray powder; yield: 0.88 mg (48%); 
1
H-
NMR 300 MHz (DMSO) δ (ppm): 6.97 (s, 1H), 3.68 (t, 4H), 3.39 (t, 4H), 1.41 (s, 9H).  
2.1.3.3. Synthesis of (2,6-dichloropyrimidin-4-yl)-(4-trifluoromethoxyphenyl)-amine {M3 
(17)} 
TLC (CHCl3: hexane (80:20; v: v)), Rf =1.8/ 6.1= 0.29; white powder; yield: 1.18 g (67%);
 1
H-
NMR 300 MHz (DMSO) δ (ppm): 10.41(s, 1H), 7.68(d, 2H), 7.40(d, 2H), 6.79 (s, 1H); FT-IR 
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(KBr) (cm
-1
): 3311.3(N-H) stretching, 3231.5,3178 Ar-H (C-H stretch), 1568.27 & 1508.3 (C=C) 
aromatic & (C=N) stretching, 838.56 & 819.89 Ar-H (H2C=CH2 bending), 967.28 (C-Cl 
stretch),704.67(C-F stretch). 
The compound (4,6-dichloropyrimidin-2-yl)-(4-trifluoromethoxyphenyl)-amine (23) was 
collected from the same column chromatography purification step as a minor product. 
2.1.3.4. (4,6-dichloropyrimidin-2-yl)-(4-trifluoromethoxyphenyl)-amine {M9 (23)}: 
 TLC (CHCl3: hexane (80:20; v: v)), Rf =3.2/ 5.2= 0.61; Off-white powder; yield: 0.3g (17%); 
1
H-
NMR 300 MHz (DMSO) δ (ppm):  10.58(s, 1H), 7.73(d, 2H), 7.34(d, 2H), 7.21 (s, 1H).  
2.1.3.5. Synthesis of 2,4-dichloro-6-[4-(5-trifluoromethylpyridin-2-yl)-piperazin-1-
yl]pyrimidine  {M4 (18)} 
TLC (DCM: hexane (40:60; v: v)), Rf =1.5/6= 0.25; white powder; yield: 1g (49%); 
1
H-NMR 300 
MHz (DMSO) δ (ppm):
 
8.4(s, 1H), 7.79(d, 1H), 7.40(d, 1H), 6.95 (s, 1H), 3.75 (t, 8H).  
2.1.3.6. Synthesis of 2,4-dichloro-6-[4-(3-trifluoromethylpyridin-2-yl)-piperazin-1-
yl]pyrimidine {M5 (19)}  
TLC (CHCl3: hexane (80:20; v: v)), Rf = 1.33/ 6= 0.22; white powder; yield: 0.65g (51%);
 1
H-NMR 
300 MHz (DMSO) δ (ppm): 8.53(d, 1H), 8.09(d,1H), 7.21 (s,1H), 7.06 (t,1H), 3.77(t,4H), 3.29 
(t,4H).  
2.1.3.7. Synthesis of 2,4-dichloro-6-(4-phenylpiperazin-1-yl)-pyrimidine {M6 (20)} 
TLC (DCM), Rf = 2/6= 0.3; white powder; yield: 0.75g (44%); 
1
H-NMR 300 MHz (DMSO) δ 
(ppm): 7.23(d, 2H), 7.09 (s, 1H), 6.96 (d, 2H), 6.81(s, 1H), 3.79(t, 4H), 3.21(t, 4H).  
2.1.3.8. Synthesis of 2,4-dichloro-6-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrimidine {M7 (21)}. 
TLC (DCM: EtOAc (80: 20; v: v)), Rf= 3/5.3= 0.56; white powder; yield: 0.68g (41%); 
1
H-NMR 
300 MHz (DMSO) δ (ppm): 8.39 (d, 2H), 7.06 (s, 1H), 6.67(t, 1H), 3.78 (t, 4H), 3.32(t, 4H). 
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2.1.4. Synthesis of symmetric analogues of 2,4-diamino-6-chloropyrimidine (MY1 (24), MY2 
(25), MY13 (36)) 
In a 25 ml round bottom flask, 2,4,6-trichloropyrimidine (1) (1g, 5.45 mmol) was dissolved in (15 
ml) solvent (isopropanol or dioxane). The mixture was then treated with aliphatic or aromatic amine 
(2.0 mmol) in the presence of base (5.0 mmol) at room temperature. While stirred, the mixture was 
heated at reflux for 15-22 hour until completion of the reaction. The reaction progress was followed 
using TLC. After the reaction completion volatiles were removed under reduced pressure using 
rotary evaporator. The residue was extracted using ethyl acetate and water (30ml X 3). The organic 
fractions were pooled and dried using sodium sulfate (Na2SO4). Ethyl acetate was removed under 
reduced pressure to dryness. The crude material was purified by silica gel column chromatography 
using CHCl3: hexane (80: 20; v: v) as eluents to give 2,4-diamino-6-chloropyrimidine. 
2.1.4.1. Synthesis of 6-chloro-N2,N4-bis(4-(trifluoromethoxy)phenyl)pyrimidine-2,4-diamine 
{MY1 (24 )} 
TLC (DCM: EtOAc (90:10; v: v)); Rf = 2.25/4.3= 0.52; white powder; yield: 0.7g (28%); 
1
H-NMR 
300 MHz (DMSO) δ (ppm): 9.78(s, 2H); 7.68(d, 4H); 7.26(dd, 4H); 6.22 (s, 1H); FT-IR (KBr) (cm-
1
): 3248.48 (N-H) stretching, 3012.5 Ar-H (C-H stretch), 2965 CH2 (C-H stretch), 1574.37,1506.9 
(C=C) aromatic & (C=N) stretching, 747.16 & 696.83 Ar-H (H2C=CH2 bending),870.38(C-Cl) 
stretch, 800.8(C-F) stretch. 
2.1.4.2. Synthesis of 4,4'-(6-chloropyrimidine-2,4-diyl)bis(1-(5-(trifluoromethyl)pyridin-2-yl) 
piperazine) {MY2 (25)} 
TLC (DCM: EtOAc (90: 10; v: v)); Rf = 2/5.6= 0.35; white powder; Yield: 2.4g (77%); 
1
H-NMR 
300 MHz (DMSO) δ (ppm): 8.41(s, 2H); 7.81(d, 2H); 9.96 (d, 2H); 6.23 (s, 1H); 3.72 (t,16H); FT-
IR (KBr) (cm
-1
): 2984.9 Ar-H (C-H stretch), 2942.9 CH2 (C-H stretch), 1474.37,1444.02 (C=C) 
aromatic & (C=N) stretching, 814.41,779.91, 761.26 Ar-H (H2C=CH2 bending), 858.17(C-Cl) 
stretch, 728.28 (C-F) stretch. 
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2.1.4.3.  Synthesis of di-tert-butyl 4,4'-(6-chloropyrimidine-2,4-diyl)bis(piperazine-1-
carboxylate)  MY13 (36) 
TLC (DCM: EtOAc (80: 20; v: v)); Rf=3.9 /5.5=0.7; light brown powder; Yield: 1g (53%); 
1
H-
NMR 300 MHz (DMSO) δ (ppm): 6.18 (s, 1H); 3.61 (t, 8H); 3.32 (t, 8H); 1.40 (s, 18H). 
2.1.5. Synthesis of 2,4-diamino-6-chloropyrimidine derivatives: (26, 27, 28, 29, 30, 31, 32, 33, 
34, 35) 
In a 25 ml round bottom flask, 4-amino-2,6-dichloropyrimidine (1.0 mmol) prepared from the 
previous procedure was dissolved in (10 ml) solvent (butanol or dioxane). The mixture was then 
treated with aliphatic or aromatic amine (2.0 mmol) in the presence of DIEPA (5.0 mmol) at room 
temperature. While stirred, the mixture was heated at reflux for 15-72 hour until completion of the 
reaction. The reaction progress was followed using TLC. After the reaction completion volatiles 
were removed under reduced pressure using rotary evaporator. The residue was extracted using 
ethyl acetate and water (30ml X 3), The organic fractions were pooled and dried using sodium 
sulfate (Na2SO4). Ethyl acetate was removed under reduced pressure to dryness. The crude material 
was purified by silica gel column chromatography using DCM: hexane (80: 20; v: v) as eluent to 
give 2,4-diamino-6-chloropyrimidine in 44-85% yield. 
2.1.5.1. Synthesis of {6-chloro-2-[4-(5-trifluoromethylpyridin-2-yl)-piperazin-1-yl]-pyrimidin-
4-yl}-(4-trifluoromethoxyphenyl)-amine {MY3 (26)} 
TLC (CHCl3); Rf =1.5/5.3=0.28; Yield: 0.21g (44%); off-white powder; 
1
H-NMR 300 MHz 
(CDCl3) δ (ppm):
 
9.73(s, 1 N-H); 8.44(s, 1H); 7.84(d, 1H); 7.74 (d, 2H); 7.36(d, 2H). 6.99 (d, 1H), 
6.10 (s, 1H), 3.79 (t, 8H); 
13
C{1H}-NMR (DMSO, δ ppm), 160.97, 160.45, 158.75, 139.31, 122.10, 
121.29, 106.73, 94.97, 44.17, 43.57, 40.75, 40.48, 40.20, 39.92, 39.64, 39.37, 39.09. FT-IR (KBr) 
(cm
-1
): 3366.6 (N-H) stretching, 2854.1 Ar-H (C-H stretch), 1620.56, 1567(C=C) aromatic & 
(C=N) stretching, 1498.3 (C-H) bending, 842.7 & 789.62 Ar-H (H2C=CH2 bending), 810.17(C-Cl) 
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stretch, 708.02 (C-F) stretch, HPLC Rt 8.189 minute; ESI-MS m/z calculated for C21H17ClF6N6O 
518.84, found 519.04 (M +H)
+
. 
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                                Figure 2.1: Chemical structure of {MY3 (26)} 
 
Table 2.1: NMR data of compound 26 
Position 
1
H-NMR (ppm) 
13
C-NMR (ppm) 
1 - 44.17 (C) 
2 - 122.10 (C) 
3, 3' 7.74 (d,2H) 40.20 (CH) 
4, 4' 7.36 (d,2H) 40.48 (CH) 
5 - 106.73 (C) 
6 9.73 (s,1H) - 
7 - 160.97 (C) 
8 6.10 (s,1H) 39.64 (CH) 
9 - 158.75 (C) 
10 - 160.45 (C) 
11, 11' 3.79 (d,8H) 39.09(CH2) 
12, 12' 3.79 (d,8H) 39.37(CH2) 
13 - 139.31(C) 
14 6.99 (d,1H) 39.92 (CH) 
15 7.84 (d,1H) 94.97 (CH) 
16 - 43.57(C) 
17 8.44 (s,1H) 121.29 (CH) 
18 - 40.75(C) 
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2.1.5.2.  Synthesis of [6-chloro-2-(4-phenylpiperazin-1-yl)-pyrimidin-4-yl]-(4 trifluoromethoxy 
phenyl)-amine {MY4 (27)} 
TLC (DCM: EtOAc (90: 10; v: v); Rf =2.2/5.2=0.4; dark brown oily compound; Yield: 0.5g (72%);  
1H-NMR 300 MHz (DMSO) δ (ppm): 9.64 (s, 1H); 7.65 (d, 2H); 7.27 (d, 2H), 7.16 (d, 2H); 6.93 
(d, 2H); 6.73 (t,1H);  6.02 (s,  1H); 3.77(t,4H); 3.23(t,  4H).  
2.1.5.3. Synthesis of [6-chloro-2-(4-pyridin-4-yl-piperazin-1-yl)-pyrimidin-4-yl]-(4-trifluoro 
methoxyphenyl)-amine {MY5 (28)} 
TLC (DCM: EtOAc (90: 10; v: v) ), Rf=2.4/5.7=0.4; yellow powder; Yield: 0.51g  (85%); 
1
H-NMR 
300 MHz (DMSO) δ (ppm): 9.68 (s, 1H); 8.15 (d, 2H); 7.69 (d, 2H); 7.30 (d, 2H); 6.84 (d, 2H); 
6.05 (s, 1H); 3.78 (t, 2H); 3.45(t, 2H). FT-IR (KBr) (cm
-1
):3092.95 (N-H) stretching, 2964.11 Ar-H 
(C-H) stretch, 1566.76, 1501.7(C=C) aromatic & (C=N) stretching, 1349.77(C-H) bending, 
951.37(C-Cl) stretch, 799.7 Ar-H (H2C=CH2) bending, 718.42(C-F) stretch. 
2.1.5.4. Synthesis of {6-chloro-2-[4-(3-trifluoromethylpyridin-2-yl)-piperazin-1-yl]-pyrimidin-
4-yl}-(4-trifluoromethoxyphenyl)-amine {MY6 (29)} 
TLC (DCM ), Rf =2.5/5.3=0.45 ; off-white powder; Yield: 0.57g (71%); 
1
H-NMR 300 MHz 
(DMSO) δ (ppm): 9.67 (s, 1H); 8.53 (d, 1H); 8.08 (d,1H); 7.70 (d, 2H); 7.29 (d, 2H); 7.11 (t,1H); 
6.07(s,1H); 3.8 (t,4H); 3.28 (t, 4H). FT-IR (KBr) (cm
-1
): 3275.21(N-H) stretching, 2983.6, 2902.7, 
2845.08 Ar-H (C-H stretch), 1567.46, 1505.63(C=C) aromatic & (C=N) stretching, 1442.68(C-H) 
bending, 860.8 (C-Cl) stretch, 795.46, 781.41 Ar-H (H2C=CH2) bending, 739.86(C-F) stretch. 
2.1.5.5. Synthesis of [6-chloro-2-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrimidin-4-yl]-(4 trifluoro 
methoxyphenyl)-amine {MY7 (30)} 
TLC (DCM: EtOAc (80: 20; v: v); Rf = 3.4/4.8= 0.7; Yield: 0.51 g (72%); off-white powder; FT-IR 
(KBr) (cm
-1
): 3271.24(N-H) stretching, 2993.5, 2898.85 Ar-H (C-H stretch), 1473.28, 1440.35 
(C=C) aromatic & (C=N) stretching, 1392.11, 1355.74 (C-H) bending, 854.51(C-Cl) stretch, 
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982.72, 809.81, 787.38 Ar-H (H2C=CH2) bending. ESI-MS m/z calculated for C19H17ClF3N7O 
451.83, found 452.07 (M +H) 
+
. 
2.1.5.6. Synthesis of 4-{6-chloro-2-[4-(5-trifluoromethylpyridin-2-yl)-piperazin-1-yl]pyrimidin 
-4-yl}-piperazine-1-carboxylic acid tert-butyl ester {MY8 (31)} 
TLC (DCM: EtOAc (80: 20; v: v); Rf =3.2/5.5=0.58, Yield: 0.35 g (74%); yellowish oil ; 
1
H-NMR 
300 MHz (DMSO) δ (ppm): 8.45 (s, 1H); 7.84 (d, 1H); 6.98 (d,1H); 6.23 (s, 1H); 3.73 (t, 8H); 3.59 
(t,4H); 2.07(s,4H); 1.42 (s, 9H). 
2.1.5.7.    Synthesis of {4-chloro-6-[4-(5-trifluoromethylpyridin-2-yl)-piperazin-1-yl]-
pyrimidin-2-yl}-(4-trifluoromethoxyphenyl)-amine {MY9 (32)} 
TLC (DCM: EtOAc (90: 10; v: v); Rf =2.3/5.6=0.41; off-white powder; Yield: 0.4g (72%);  
1
H-
NMR 300 MHz (DMSO) δ (ppm): 9.76(s,1H), 8.45 (s, 1H); 7.82 (d, 2H); 7.62 (d,1H); 7.33 (d, 2H); 
7.05 (d,1H); 6.47 (s, 1H); 3.69 (t, 8H).  
2.1.5.8. Synthesis of 6-chloro-N4-(4-fluorophenyl)-N2-(4-trifluoromethoxyphenyl)pyrimidine-
2,4-diamine {MY10 (33)} 
In a 25 ml round bottom flask (1g, 3.1 mmol) of 4,6-dichloropyrimidin-2-yl)-(4-
trifluoromethoxyphenyl)-amine {M9 (23)} was dissolved in 10 ml dioxane. To the reaction (0.38g, 
3.4 mmol) of 4-fluoroaniline (2) and conentrated HCl were added. The mixture then was stirred at 
reflux for 145 hours until the completion of the reaction. The reaction progress was followed by 
TLC (DCM). After the reaction completion volatiles were removed under reduced pressure using 
rotary evaporator. The residue was extracted using ethyl acetate and water (30ml X 3). The organic 
fractions were pooled and dried using sodium sulfate (Na2SO4). Ethyl acetate was removed under 
reduced pressure to dryness. The crude material was purified by silica gel column chromatography 
using DCM: hexane (90: 10; v: v) as eluent to afford the compound (33).  
 TLC (DCM: EtOAc (90: 10; v: v); Rf=2.3/5.6=0.41, Yield: 0.7g (57%) off-white powder; 1H-
NMR 300 MHz (DMSO) δ (ppm): 7.94(d,4H),7.60 (t,2H), 7.45(d,4H), 6.21(s, 1H), 3.66(t, 16H). FT-
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IR (KBr) (cm
-1
): 3242.62 (N-H) stretching, 3088.02 Ar-H (C-H stretch), 1577.55, 1505 (C=C) 
aromatic & (C=N) stretching, 1421.93, 1392.11(C-H) bending, 853.51(C-Cl) stretch, 802.86, 
785.44 Ar-H (H2C=CH2) bending, 733.58(C-F) stretch. 
2.1.5.9. Synthesis of (6-chloro-2-piperazin-1-yl-pyrimidin-4-yl)-(4-fluorophenyl)-amine 
{MY11 (34)} 
In a 25 ml round bottom flask (0.8g , 3.1 mmol) of (2,6-dichloropyrimidin-4-yl)-(4-fluorophenyl)-
amine {M1 (15)} were dissolved in 15 ml dioxane and then treated with (0.64g, 3.45 mmol) of 
BOC-piperazine (4) in the presence of (2 ml , 12.6 mmol) of DIPEA. The mixture then was stirred 
at reflux at 100 °C for 110 hours until the completion of the reaction. The reaction progress was 
followed by TLC (CHCl3). After the reaction completion volatiles were removed under reduced 
pressure using rotary evaporator. The residue was extracted using ethyl acetate and water (30ml X 
3). The organic fractions were pooled and dried using sodium sulfate (Na2SO4). Ethyl acetate was 
removed under reduced pressure to dryness. The crude material was purified by silica gel column 
chromatography using DCM: hexane (70: 30; v: v) as eluent to afford the compound (34).  
TLC (DCM: EtOAc (90:10; v: v)), Rf=2.8/5.1=0.5; white powder; yield: 0.65g  (51%) ; 
1
H-NMR 
300 MHz (DMSO) δ (ppm): 9.53 (s, 1H); 7.56 (d, 2H); 7.18 (d,2H); 6.02 (s, 1H); 3.65 (t, 4H); 3.37 
(t,4H); 1. 42 (s, 9H). 
2.1.5.10. Synthesis of 4-[4-chloro-6-(4-fluorophenylamino)-pyrimidin-2-yl]-piperazin-1-yl}-
phenylmethanone {MY12(35)} 
In a 25 ml round bottom flask 0.5g of (6-chloro-2-piperazin-1-yl-pyrimidin-4-yl)-(4-fluorophenyl)-
amine {MY11 (34)} was dissolved in (10 ml) EtOH and acidified by 0.3 ml concentrated HCl and 
stirred for 6 hours. Then the mixture was allowed to cool in ice-bath overnight, and the precipitate 
was filtered off. The precipitate was washed with additional 10 ml ethanol and filtrates were 
collected and evaporated to dryness to give a 0.45g white precipitate of corresponding (6-chloro-2-
piperazin-1-yl-pyrimidin-4-yl)-(4-fluorophenyl)-amine hydrochloride salt. (0.35g, 1.13mmol) of the 
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latest salt was then dissolved in 10 ml pyridine and then treated with (0.77g, 5.5 mmol) of benzoyl 
chloride (11) in the presence of (785μl, 5.65 mmol) DIPEA. The mixture then was stirred at reflux 
for 48 hours until the completion of the reaction. The reaction progress was followed by TLC 
(CHCl3). When the reaction was completed, pyridine was removed by rotary evaporator and the 
residue was extracted using ethylacetate and water (30ml X 3), traces of water are removed by 
treating the organic phase with a drying agent (Na2SO4). Then the solvent was removed under 
reduced pressure to afford 220 mg light brown powder {MY12 (35)}.  
TLC (DCM: EtOAc (90: 10; v: v)); Rf= 2.3/5.1= 0.45; yield: 0.22g (47%); light brown powder; 
1
H-
NMR 300 MHz (DMSO) δ (ppm): 9.53(s,1H),7.57(d,2H), 7.45(m,5H), 7.15(d,2H), 6.02(s,1H), 
3.72(t,8H);
13
C{1H}-NMR (DMSO-d6, δ ppm), 161.74, 158.60, 136.24, 133.18, 130.18, 129.70, 
128.92, 127.49, 122.23, 116.0, 115.71, 94.42, 40.78, 39.59, 39.39, 39.12; FT-IR (KBr) (cm
-1
): 
3290.01 (N-H) stretching, 2989.14 Ar-H (C-H stretch), 1565.07, 1502.17 (C=C) aromatic & (C=N) 
stretching, 1438.14 (C-H) bending, 855.55(C-Cl) stretch, 831.07, 803.56, Ar-H (H2C=CH2) 
bending, 705.73(C-F) stretch. HPLC Rt 8.012 minute; ESI-MS m/z calculated for C21H19ClFN5O 
411.86, found 413.19 (M +H) 
+
. 
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                                Figure 2.2: Chemical structure of {MY12 (35)} 
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Table 2.2: NMR data of compound 35 
Position 
1
H-NMR (ppm) 
13
C-NMR (ppm) 
1 - 130.18 (C) 
2, 2' 7.57(d, 2H) 39.59 (CH) 
3, 3' 7.15 (d,2H) 40.78 (CH) 
4 - 129.70 (C) 
5 9.53(s,1H) - 
6 - 161.74 (C) 
7 6.02 (s,1H) 94.42 (CH) 
8 - 133.18 (C) 
9 - 158.60 (C) 
10,10' 3.72 (t,8H) 39.39 (CH2) 
11,11' 3.72 (t,8H) 39.12 (CH2) 
12 - 136.24 (C) 
13 - 128.92 (C) 
14 7.45(m,5H) 115.71(CH) 
15 7.45(m,5H) 115.17 (CH) 
16 7.45(m,5H) 116.0 (CH) 
17 7.45(m,5H) 122.23 (CH) 
18 7.45(m,5H) 127.49 (CH) 
 
2.1.5.11. Synthesis of 4-chloro-2,6-di-piperazin-1-yl-pyrimidine hydrochloride salt MY14 (37) 
 
In a 25 ml round bottom flask 0.6g of MY13 (36) was dissolved in (10 ml) EtOH and acidified by 
0.3 ml concentrated HCl and stirred for 6 hours. Then the mixture was allowed to cool in ice-bath 
overnight, and the precipitate was filtered off. The precipitate was washed with additional 10 ml 
ethanol and filtrates were collected and evaporated to dryness to give a 0.5g white precipitate of 
corresponding 4-Chloro-2,6-di-piperazin-1-yl-pyrimidine hydrochloride salt. 
1
H-NMR 300 MHz 
(DMSO) δ (ppm): 9.19 (s, 2H); 6.36 (s, 1H); 3.85 (t, 4H); 3.10 (t, 4H). 
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2.1.5.12.  Synthesis of {4-[2-(4-benzoylpiperazin-1-yl)-6-chloropyrimidin-4-yl]-piperazin-1-yl}-
phenylmethanone MY15 (38) 
In a 25 ml round bottom flask (0.2g, 0.7 mmol) 0f 4-chloro-2,6-di-piperazin-1-yl-pyrimidine 
hydrochloride salt {MY14 (37)} was dissolved in 10 ml pyridine and then treated with (0.22g, 1.6 
mmol) of benzoyl chloride (11) in the presence of (271μl, 3.5mmol) TEA. The mixture then was 
stirred at reflux for 22 hours until the completion of the reaction. The reaction progress was 
followed by TLC (CHCl3: EtOAc (80: 20; v: v)). After the reaction completion, pyridine  was 
removed by rotary evaporator and  the residue was extracted using ethyl acetate and water (30ml X 
3), The organic fractions were pooled and dried using sodium sulfate (Na2SO4). Ethyl acetate was 
removed under reduced pressure to dryness to afford the product (38). 
TLC (CHCl3: EtOAc (80: 20; v: v)); Rf =3.5/5.2= 0.67; yield: 0.3g (87%); light brown powder; 
1
H-
NMR 300 MHz (DMSO) δ (ppm): 7.94(d, 4H), 7.60 (t, 2H), 7.45(d, 4H), 6.21(s, 1H), 3.66(t, 16H).  
2.1.6. Synthesis of 2,4,6-trisubstitutedpyrimidine (39, 40, 41, 42, 43, 44, 45, 46, 47) 
2.1.6.1. Synthesis of 6-ethoxy-N2,N4-bis(4-(trifluoromethoxy)phenyl)pyrimidine-2,4-diamine 
{MER1 (39)} 
 In a 25 ml round bottom flask, sodium metal (1.2 mmol) was dissolved in ethanol (10 ml) and 
stirred at room temperature for 30-45 minutes. To the mixture (1mmol) of 2,4-diamino-6-
chloropyrimidine derivative was then added and refluxed for 90 hours. The reaction progress was 
followed using TLC (DCM). After the reaction completion, ethanol then was removed by rotary 
evaporator. The residue was extracted using ethyl acetate and water (30ml X 3). The organic 
fractions were pooled and dried using sodium sulfate (Na2SO4). Ethyl acetate was removed under 
reduced pressure to dryness to afford the desired 2,4,6-trisubstitutedpyrimidine compounds (39). 
TLC (DCM): Rf= 3.6/5=0.75; Yield: 0.15g (75%); brown crystal; 
1
H-NMR 300 MHz (DMSO) δ 
(ppm):
  
9.36 (s, 2H), 7.74 (d, 4H), 7.24 (d, 4H), 5.57 (s, 1H), 4.29 (m, 2H), 1.3 (t, 3H). 
 57 
 
2.1.6.2. Synthesis of [6-phenoxy-2-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrimidin-4-yl]-(4-
trifluoromethoxyphenyl)-amine (41), [6-phenoxy-2-(4-phenylpiperazin-1-yl)-pyrimidin-4-yl]-
(4-trifluoromethoxyphenyl)-amine (42) and of [6-phenoxy-2-(4-pyridin-4-yl-piperazin-1-yl)-
pyrimidin-4-yl]-(4-trifluoromethoxyphenyl)-amine (43). 
In a 25 ml round bottom flask, (6 mmol) of sodium was dissolved in dried THF (tetrahydrofurane) 
(7 ml) in the presence of (3 mmol) phenol, the mixture was stirred at room temperature for 30 
minutes. Then (1mmol) of 2,4-diamino-6-chloropyrimidine derivative was added to the mixture and 
refluxed for 100-120 hours. The reaction progress was followed using TLC (DCM: EtOAc (90:10; 
v: v)). The reaction was stopped when no progress had noticed, THF was removed by rotary 
evaporator and the residue was extracted using ethyl acetate and water (30ml X 3), the organic 
fractions were pooled and dried using sodium sulfate (Na2SO4). Ethyl acetate was evaporated to 
dryness to afford an oily yellow product. A re-crystalization using hexane as solvent was made to 
purify the compound and to afford the desired compound. 
2.1.6.3. [6-phenoxy-2-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrimidin-4-yl]-(4trifluoromethoxy 
phenyl)-amine {(MER3(41)} 
 
         TLC (DCM: EtOAc (80:20 v: v)); RF=3.2/5.4=0.59; Yield: 0.05g (22%); white oily product..  
2.1.6.4. [6-phenoxy-2-(4-phenylpiperazin-1-yl)-pyrimidin-4-yl]-(4-trifluoromethoxyphenyl)-
amine {(MER 4 (42)} 
  TLC (DCM: EtOAc (80:20 v: v)); RF=3.1 /5.4=0.57; Yield: 0.050g (00%); white oily product. 
2.1.6.5. [6-phenoxy-2-(4-pyridin-4-yl-piperazin-1-yl)-pyrimidin-4-yl]-(4-trifluoromethoxy 
phenyl)-amine {(MER5 (43)} 
TLC (DCM: EtOAc (90: 10; v: v); RF=3.3/5.4=0.61; white oily product. Yield: 0.22g (21%).yellow 
oily product. 
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2.1.6.6.  Synthesis of N-(4-fluorophenyl)-N'-(4-trifluoromethoxyphenyl)-2-[4-(3 
trifluoromethylpyridin-2-yl)-piperazin-1-yl]-pyrimidine-4,6-diamine (44), N-(4-fluorophenyl)-
2-(4-pyrimidin-2-yl-piperazin-1-yl)-N'-(4-trifluoromethoxyphenyl)-pyrimidine-4,6-diamine 
(45) 
In a 25 ml round bottom flask 2,4-diamino-6-chloropyrimidine (1 mmol)  was dissolved in dioxane 
(10 ml). To the mixture 4-fluoroaniline (1.1 mmol) and 200μl of concentrated HCl were added at 
room temperature. While stirred, the mixture was heated at reflux for 40- 48 hours and followed by 
TLC (DCM: EtOAc (80:20; v: v)).The reaction was stopped when no progress had noticed. Dioxane 
was removed by rotary evaporator and the residue was extracted using ethyl acetate and water 
(30ml X 3). The organic fractions were pooled and dried using sodium sulfate (Na2SO4). Ethyl 
acetate was removed under reduced pressure to dryness. The resulting crude was purified by re-
crystallization using DCM as solvent to purify the mixture and to afford the desired compounds. 
2.1.6.7. N-(4-fluorophenyl)-N'-(4-trifluoromethoxyphenyl)-2-[4-(3 trifluoromethylpyridin-2-
yl)-piperazin-1-yl]-pyrimidine-4,6-diamine {(MER6(44)} 
TLC (DCM: EtOAc (80:20; v:v)); RF=3.9/5.6=0.69; brown oil; Yield: 0.45g (20%).  
2.1.6.8. N-(4-fluorophenyl)-2-(4-pyrimidin-2-yl-piperazin-1-yl)-N'-(4-trifluoromethoxyphenyl) 
-pyrimidine-4,6-diamine {(MER7(45)} 
  TLC (DCM: EtOAc) (80:20; v: v)); Rf= (4.3/6.5)= 0.66; Yield: 0.05g (26%); brown crystal. 
2.1.6.9. Synthesis of {4-[4-(4-benzoylpiperazin-1-yl)-6-(2-hydroxyethylamino)-pyrimidin-2-
yl]-piperazin-1-yl}-phenylmethanone {MRE8 (46)} 
In a 25 ml round bottom flask (0.12g, 0.24 mmol) of {4-[2-(4-benzoyl-piperazin-1-yl)-6-chloro-
pyrimidin-4-yl]-piperazin-1-yl}-phenyl-methanone (MY15) (38) was dissolved in 10 ml dioxane 
and then treated with (0.018g, 0.29 mmol) of ethanolamine (12) in the presence of (0.1g, 0.72mmol) 
K2CO3. The mixture then was stirred at reflux for 25 hours until the completion of the reaction. The 
reaction progress was followed by TLC (DCM: EtOAc (80:20; v:v)) .When the reaction was 
completed, dioxane was removed by rotary evaporator and the residue was extracted  using 
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ethylacetate and water (30ml X 3), traces of water are removed by treating the organic phase with a 
drying agent (Na2SO4). Then the solvent was removed under reduced pressure to afford the desired 
compound.  
TLC (DCM: EtOAc (80: 20; v: v)), Rf= 4.2/6.5=; white powder; Yield: 0.04g (33%)
.
 
Table 2.3: list of synthesized compounds and their chemical and structural formula.  
Com. 
# 
Com. 
code 
R1 R2 R3 Chemical 
formula 
M.wt yeild 
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M1 H2N F
 
 
Cl 
 
Cl 
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O
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N
N NH
 OH 
C25H22F3N7O2 
 
509 22% 
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2.2. Comuptational Chemistry 
Computer-aided prediction of biological activity of synthesized compounds 
The Biological activity is the result of chemical compound's interaction with biological entity. This 
Biological activity depends on peculiarities of compound (structure and physicochemical 
properties), biological entity (species, sex, age, etc.), mode of treatment (dose, route, etc.).
[115]  
On 
the contrary, the biological potential of compound includes all activities, which can be discovered 
under some specific experimental conditions. The biological potential called the biological activity 
spectrum. 
[116] 
Biological activity spectrum of compound can be predicted on the basis of structure-
activity relationships found by the analysis of the known data from the training set. Based on the 
analysis of large training set consisting of tens of thousands of the known biologically active 
compounds, computer program PASS (Prediction of Activity Spectra for Substances) provides the 
means to evaluate any new compound in huge chemical-pharmacological space.
[117]
  
Computer program PASS is the product of ideas originated more than 25 years ago within the 
framework of the National Registration System of New Chemical Compounds organized in the 
USSR in 1972.
[118]
 It was V.Avidon who suggested that many classes of biological activity could be 
predicted on the basis of structural formulae of chemical compounds. Similar approach was under 
development by V. Golender and A. Rozenblit. 
[119]
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Prediction using the sofware Prediction of Activity Spectra for Substances (PASS) 
 
 To predict the bioactivity of our compounds we were assisted by the software Prediction of 
Activity Spectra for Substances (PASA). PASS predicts simultaneously several hundreds of 
biological activities (pharmacological main and side effects, mechanisms of action, mutagenicity, 
carcinogenicity, teratogenicity and embryotoxicity).
[120]
 The biological activity spectrum of a 
compound presents all compounds' actions despite the difference in essential conditions of its 
experimental determination. If the difference in species, sex, age, dose, route, etc. is neglected, the 
biological activity can be identified only qualitatively. Thus, "the biological activity spectrum" is 
defined as the "intrinsic" property of a compound depending only on its structure and physico-
chemical characteristics.
[115]
  
Prediction of this spectrum by PASS is based on SAR analysis of the training set containing more 
than 35,000 compounds which have more than 500 kinds of biological activity. Therefore, PASS 
once trained is able to predict simultaneously all biological activities which are included in the 
training set. To provide the best quality of prediction new information about biologically active 
compounds is collected permanently from papers and electronic sources and, after the experts' 
evaluation, is regularly added to the training set. [121] 
Chemical descriptors used in PASS analysis, called multilevel neighborhoods of atoms (MNA), are 
recently considered in detail. They are automatically generated by on the basis of MOL-file of a 
molecule. The list of MNA descriptors currently consists of more than 35700 different items. The 
new ones are added to this list being founded in a novel compound refreshing the training set. MNA 
descriptors are effectively applied in SAR, QSAR and similarity analysis. They can be also used as 
keys or fingerprints to cluster the libraries of chemical compounds, to select the representative sub-
sets from chemical databases, etc.
[115]
 
 63 
 
PASS algorithm was selected by theoretical and empirical comparison of many different 
mathematical methods to provide high accuracy of prediction and robustness of calculated 
estimates. It was shown that the mean accuracy of prediction with PASS is about 86% in LOO 
cross-validation. Using MDDR database to create heterogeneous training and evaluation sets it was 
recently demonstrated that the predictions are robust despite excluding up to 60% of information. 
PASS uses CSV, SD or MOL-files as input and the results of prediction (output) can be obtained as 
TXT or SD-files. Since the prediction of biological activity spectra for 1,000 compounds in usual 
PC takes about 1 minute, PASS can be effectively applied to predict biological potential of separate 
compounds and to analyze large chemical databases.
[115]
 
2.3. Biological studies 
 
The newly synthesized compounds compounds were tested against their biological activity at the 
lab of Professor Bjørn Tore Gjertsen; Department of Clinical Science. University of Bergen-
NORWAY. 
Cell line 
Acute monocytic leukemia (Molm-13) cell line had been utilized. Molm-13 was obtained from a 20 
years old Acute Myeloid Leukemia (AML) patient. This cell line had been stably transfected by sh-
RNA (empty vector) and sh-p53 RNA (sh-p53).
 [122]
  
In vitro Assay  
The viability of the cells was determined using WST-1 assay. The assay is based on the conversion 
of the tetrazolium salt WST-1 into a colored dye by mitochondrial dehydrogenase enzymes. The 
soluble salt is released into the media, and within a given time period, the reaction produces a color 
change which is directly proportional to the amount of mitochondrial dehydrogenase in a given 
culture as shown in. As a result, the assay actually measures the net metabolic activity of cells 
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treated by the compound. Theoretically, this is reflective of cell number and can be adopted for use 
in measuring cell viability at specific concentrations.
[123]
  
Medium 
RPMI 1640 Medium was used to perform biological testing of compounds. This medium was 
originally developed by Moore and his colleagues at Roswell Park Memorial Institute (RPMI) in 
1966. RPMI has successfully been used for the cultivation of normal human and neoplastic 
leukocytes.It has been widely used in fusion protocols and in the growth of hybrid cells.
[124]
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Chapter 3 
 
Results and Discussion 
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3. Results and Discussion: 
The major challenge facing treatments for tumors is to overcome resistance developed following 
repeated administration of chemotherapeutics. Controlling the transcription of ER and/or AR-
regulated genes by directly inhibiting the interaction of the (ER)/ (AR) with coactivator proteins 
may provide an alternative mechanism for blocking estrogen or androgen and restrict their activity 
in breast or prostate cancer offering a solution for the resistance.  
3.1. Chemical synthesis of compounds  
 
Pyrimidine core scaffolds bearing multiple functionality that may be transformed into a widely 
diverse range of functionalized derivatives by a sequence of efficient and regioselective reactions 
are becoming increasingly important. Pyrimidines are electron-deficient aromatic systems and, 
when halogenated, become very useful substrates for a variety of nucleophilic aromatic substitution 
(S
N
Ar) processes. Due to the numerous commercial availability of chloro and poly-
chloropyrimidines, many synthetic strategies concerned with creating pyrimidine-based libraries 
from halogenated core scaffolds were reported. In the current study 2,4,6-trichloropyrimidine is 
used as the core scaffold. However, since regioisomeric products are formed in nucleophilic 
aromatic substitution stages, separation steps of isomers is required following each step, making 
adoption of this scaffold less likely. Therefore, there remains a requirement for efficient synthetic 
methodology that allows the synthesis of regioselective polysubstituted pyrimidines in sequential 
nucleophilic aromatic substitution. Such synthetic methods might help in meeting the demand for 
rapid analogue synthesis (RAS) techniques for applications in parallel synthesis.
[125]
  
Reactions of 2,4,6-trichloropyrimidine with amines or other nucleophiles suffers from poor 
selectivity and diminished regioselectivity, producing mixtures of the 2-substituted and 4-
substituted regioisomers (I, II) [Scheme 3.1] respectively. Moreover, separation and identification 
of isomers 2-substituted and 4-substituted may be difficult. Purification must be performed to 
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remove the 2-substituted regioisomer from the mixture before further reactions can be carried out. 
However, 4-substituted derivatives can be isolated in acceptable yields, further selective 
functionalization of 4-substituted to form either IV or V [Scheme 3.1] may be similarly 
complicated.
[126]
 
One problem which in using of 2,4,6-trichloropyrimidine as starting material is related to the 
reactivity of the three chloride atoms: the formation of the bond between the nucleophilic group and 
the link group may involve practically any of the three atoms, which is a challenging factor 
obtaining and purifying the desired  product with acceptable yields. 
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Scheme 3.1: Sequential substitution of the of 2,4,6-trichloropyrimidine by various nucleophiles. 
Typical methods for preparation of monosubstituted (I, II), disubstituted (III, IV, V), and 
trisubstituted pyrimidines (VI, VII, VIII). Nuc: Nucleophile. 
 
As indicated in [Scheme 3.1] three groups of compounds have been synthesized in the course of the 
current study. The final products classified as 2,4,6-trisubstituted pyrimidines were synthesized in a 
way to mimic the LXXLL coactivator peptide with a hydrophobic functional groups mimicking the 
leucine residues in the LXXLL motif, and with a functional groups at the termini to compliment the 
“charge clamp” of the NR box binding site for the ERα and/or AR. 
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3.1.1. Step-1: Mono-aminosubstituted pyrimidines (15, 16, 17, 18, 19, 20, 21, 23). 
At this stage we aimed at exploring the possibility of introducing different nucleophilic moieties 
(amines, alkoxides, etc...) as first substituents on the pyrimidine. The reaction was done using 
reported procedures according to the type of the nucleophile. In case of the first amination a 
procedure described by Vasudeva Sagi et al. was followed.
[34]
 The 4-monoamino-2,6-
dichloropyrimidines (15, 16, 17, 18, 19, 20, 21, 23) were synthesized using dioxane as solvent 
instead of ethanol, DIPEA instead of Na2CO3 see [Scheme 3.2]. In agreement with the other 
studies, it was noticed that despite a preference toward the 4-position the reaction was not totally  
regioselective  
[127],[126]
.  Thus, mixtures of the 4-amino isomer (major) and 2-amino isomer (minor) 
were obtained indicating that chloride residing at position-4 is often more labile than the one at 
position-2. Separation of the two isomers was accomplished using column chromatography prior 
proceeding to the next step (see [Scheme 3. 2] below). 
Scheme 3. 2: General strategy for the synthesis of monoaminopyrimidine derivatives 
NN
Cl Cl
Cl
2,4,6-trichloropyrimidine
NN
Cl R1
Cl
NN
Cl Cl
R1
+
2
46
4-amino-2,6-dichloro 
pyrimidine
2-amino-4, 6-dichloro
pyrimidine
(1)
major minor
(a)
 
Reagents and conditions: a) Dioxane, DIPEA. R1= aliphatic or aromatic amine, stirring at reflux 
100 ˚C for 8-12 hours. 
 
3.1.1.1. Synthesis of (4-amino-2,6-dichloropyrimidine) derivatives (15-21, 23)  
The planned compounds were prepared starting from the commercially available 2,4,6 
trichloropyrimidine (1) that was reacted with different aromatic amines (anilines derivatives) 
[Scheme 3.3] or aliphatic amines (piperazine derivatives) [Scheme 3.4] under  basic conditions 
using DIPEA as a base and dioxane as solvent. The nucleophilic displacement of the chloro group 
by amines took place under elevated temperatures and a mixture of the 2-amino and 4-amino 
regioisomers was produced. Following evaporation of volatiles and washing with distilled water the 
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two isomers were purified by column chromatography using CHCl3:hexane (40: 60; v: v). Although 
these two sets of compounds have been prepared under the same conditions a difference in the 
percentage of yields was noticed. The 4-anilinopyrimidine derivatives were isolated in good yields 
that range between 64% for (15) to 67% for (17) . While the 4-aminopyrimidines with piperazine 
derivatives had been isolated (41%-51%) yields. Purified intermediates 4-aminopyrimidines (15-21) 
were used in the next steps.  
The 2-aminopyrimidine derivative (23) which is the isomeric product of (17) resulted from reaction 
of (1) and (3) was collected as a white powder in 17% yield and also used in further reactions. 
Scheme 3.3: Representative procedure for the synthesis of (4-amino-2,6-dichloropyrimidine) 
derivatives (15, 17, 23). 
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F
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2
4
67%
17%
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R
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Reagents and conditions: a) Dioxane, DIPEA, stirring 8 hours for 15, 17, 23 at 100 ˚C, 
evaporation, extraction, column chromatography. 
 
Piperazine nucleus is important aliphatic heterocyclic moiety that is found in various compound 
classes that exhibit wide range of pharmacological activities including antipsychotic, 
anticonvulsant, antiarrhythmic, antimicrobial, antioxidant, antimalarial, and cytotoxic activities.
[128]
 
Different piperazine derivatives were introduced to pyrimidine core such as (BOC-piperazine (4), 
(5), 1-(3-trifluoromethyl-pyridin-2-yl)-piperazine (6), phenylpiperazine (7), 2-(1-
piperazinyl)pyrimidine (8). 
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Scheme 3.4: Representative procedure for the synthesis of (4-amino-2,6-dichloropyrimidine) 
derivatives (16, 18, 19, 20, 21). 
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F
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N
F
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M6 (20)
M7 (21)
4
N
R
48%
44%
51%
44%
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Reagents and conditions: a) Dioxane, DIPEA, stirring 9 hours for 18, 10 hours for 16, 12 hours 
for 19, 20 and 21 at 100 ˚C, evaporation, extraction, column chromatography. 
 
 
3.1.2. Step-2: Synthesis of 2, 4-diamino-6-chloropyrimidine: 
To prepare the 2,4-diamino-6-chloropyrimidines (26, 27, 28, 29, 30) the purified 4-amino-2,6-
dichloropyrimidine (17) was reacted with desired  amine. It was noticed that the introduction of the 
first amine at position-2 induces significant deactivation toward the following amination.  Hence the 
need for elevated reaction temperature, high concentrations of  nucleophiles and prolonged times to 
drive reactions to completion.
[129]
 The procedure described previously by Vasudeva Sagi et al. was 
followed using (2.0 mmol) of the nucleophiles in the presence of DIPEA resulting in displacement 
of chloro group on position-2 of pyrimidine core
[34]
 (see [Scheme 3.5] below). 
Scheme 3.5:-General strategy for the synthesis of disubstitutedpyrimidine derivatives. 
NN
Cl X1
Cl
4-amino-2, 6-dichloro 
pyrimidine
NN
Cl X1
X2
2, 4-diamino-6-
chloropyrimidin
(a)
 
Reagents and conditions: (a) DIPEA, butanol, reflux at 100 °C, extraction, column 
chromatography using CHCl3: hexane (80: 20; v: v). X1, X2= aliphatic or aromatic amine. 
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3.1.2.1. Synthesis symmetric of 2,4-diaminopyrimidine  analogues (24, 25, 36). 
These compounds were synthesized in one step by reacting 1.0 equivalent of (1) with 2.0 
equivalents of either the aliphatic or aromatic amines. 6-chloro-N2,N4-bis(4-
(trifluoromethoxy)phenyl) pyrimidine-2,4-diamine (24) was synthesized using  4-
trifluromethoxyaniline (3) in isopropanol for 22 hours, while for the compound 4,4'-(6-
chloropyrimidine-2,4-diyl)bis(1-(5-(trifluoromethyl)pyridin-2-yl)piperazine) (25), (5) used  with 
dioxane for 15 hours. (24 and 25) were purified by column chromatography using CHCl3: hexane 
(80: 20; v: v), in 28%, 77% yield respectively. It was noticed that percentage of yield was affected 
by solvents. Seemingly, the difference of about 20 ˚C degrees in the refluxing temperature of the 
two solvents could be one of the reasons for the increase in the percentage of yield.   
The synthesis of di-tert-butyl-4,4'-(6-chloropyrimidine-2,4-diyl)bis(piperazine-1-carboxylate) (36) 
1.0 equivalent of (1) was reacted with 2.0 equivalents of BOC-piperazine in the presence of DIPEA 
and 0.1g of palladium acetate (Pd(OAc)2 as catalyst (see [Scheme 3.6]). 
The reaction was over in 4 hours. However, the reaction yield was 53% indicating the effectiveness 
of Pd(OAc)2 in shortening the reaction time with no improvement in percentage yield.  
 
Scheme 3.6: Representative procedure for the synthesis of 2,4-diamine symmetrical  analogues (24, 
25, 36). 
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MY2 (25)
4
2
MY13 (36)
28%
77%
53%
 
Reagents and conditions: a) TEA, isopropanol. reflux at 100 °C for 22 hours, extraction, column 
chromatography using CHCl3: hexane (80: 20; v: v). b) DIPEA, dioxane; reflux at 100 °C  for 15 
hours, extraction, column chromatography using CHCl3: hexane (80: 20; v: v). c) DIPEA, dioxane; 
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palladium acetate, reflux at 100 °C  for 4 hours, extraction, column chromatography using CHCl3: 
hexane (80: 20; v: v). 
3.1.2.2. Synthesis of 2,4-diamino-6-chloropyrimidine analogues (26-30) 
These analogues were generated via nucleophilic substitution at C2-position of pyrimidine core in 
the presence of various piperazine derivatives in basic conditions under refluxing for about two 
weeks. (2,6-dichloropyrimidin-4-yl)-(4-trifluoromethoxyphenyl)-amine (17) was subjected to 
further derivatization at C2-position by a different piperazine derivative to generate  (26-30). In this 
series of compounds 4-trifluoromethoxyanilline was retained at C4-position while the substituent at 
C2-position was modified to give rise to asymmetric 2,4-diaminopyrimidines. 
For the synthesis of {6-chloro-2-[4-(5-trifluoromethylpyridin-2-yl)-piperazin-1-yl]-pyrimidin-4-yl}-
(4-trifluoromethoxyphenyl)-amine (26) similar reaction conditions were used M3 (17) with 1 
equivalent of (5) in the presence of 1.2 equivalent of DIPEA and dioxane. The desired compound 
was purified by column chromatography using CHCl3: hexane (70: 30; v: v) to afford 210mg off-
white powder in 44% yield. The procedure depicted below in [Scheme 3.7]. 
The other compounds (27-30) as depicted below in [Scheme 3.7] were prepared by using the same 
precursor (17) as a starting material but with different conditions in an attempt to get a higher yield. 
These reaction were performed by using tert-butanol as a solvent instead of dioxane, using 2 
equivalents of the piperazine derivatives (6), phenylpiperazine (7), (8), 1-(4-pyridyl)piperazine (9), 
and using of 5 equivalents of DIPEA. Purification through column chromatography performed and 
gave pure compounds with a percentage yield in the range (71%-85%). The improvement in 
percentage yield may be a result of equivalency increment and of using excess of reagents which 
pushed the reaction to completion. 
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Scheme 3.7: General procedure for the synthesis of asymmetric 2,4-diamino-6-chloropyrimidines 
(26-30). 
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N
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44%
72%
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Reagents and conditions: a) Dioxane, DIPEA, reflux at 100 °C for 50 hours, extraction, column 
chromatography using CHCl3: hexane (70: 30; v: v) b) DIPEA, butanol, reflux at 100 °C, for 50 hours for 
(27), 60 hours for (28), 72 hours for (29), 70 hours for (30). 
 
3.1.2.3. Synthesis of 4-{6-chloro-2-[4-(5-trifluoromethylpyridin-2-yl)-piperazin-1 
yl]pyrimidin-4-yl}-piperazine-1-carboxylic acid tert-butyl ester {MY8 (31)}, 4-[4-Chloro-6-(4-
fluorophenylamino)-pyrimidin-2-yl]-piperazine-1-carboxylic acid tert-butyl ester {MY11 (34)} 
 
These two reaction had been performed with dioxane and DIPEA to produce different asymmetrical 
2,4-diaminopyrimidine derivatives. The precursor 4-(2,6-dichloropyrimidine-4-yl)-piperazine-1-
carboxylic acid tert-butyl ester (16) treated with (5) to give MY8 (31). The precursor (2,6-
dichloropyrimidin-4-yl)-(4-fluorophenyl)-amine (15) was reacted with BOC-piperazine (2) to 
produce the compound MY11 (34). Extraction and column chromatography using CHCl3: hexane 
(70: 30; v: v) were performed to purify the compounds. The procedures depicted below in [Scheme 
3.8].  
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Scheme 3.8: Representative procedure for the synthesis of 2,4-diamino-6-chloropyrimidines (31, 
34)  
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Reagents and conditions: a) Dioxane, DIPEA, reflux 65 hours for 31, 70 hours for 34. Extraction 
and column chromatography using CHCl3: hexane (70: 30; v: v). 
  
3.1.2.4. Synthesis of {4-chloro-6-[4-(5-trifluoromethylpyridin-2-yl)-piperazin-1-yl]-pyrimidin-
2-yl}-(4-trifluoromethoxy-phenyl)-amine {MY9 (32)} and 4 -chloro-N4-(4-fluorophenyl)-N2-
(4-trifluoromethoxy-phenyl)pyrimidine-2,4-diamine {MY10(33)}. 
These two reactions differ from the previous reactions in the isomers that used as a reagent for 
starting the reaction, all the compounds (24-31, and 34) were produced from a 4-position isomer 
while the compound (32), (33) was produced from a 2-position isomer but lead to the same results 
of producing different asymmetrical 2,4-diaminopyrimidine derivatives. The compound MY9 (32) 
was produced by treating M9 (23) with 1.2 equivalents of (5) and DIPEA for 90 hours [Scheme 
3.9]. The compound MY10 (33) was produced by treating M9 (23) with 1.2 equivalents of 4-
fluoroaniline (2) in the presence of 37% HCl.The reactions were stirred at reflux until the reaction 
completed. The desired compounds were purified by extraction and column chromatography using 
CHCl3: hexane (80: 20; v: v) and collected as an off- white powders in 72% for (32) and 57% for 
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(33) [Scheme 3.9]. Using the acidic conditions for compound MY10 (33) had influenced the 
percentage of yield and the time of reaction. 
Scheme 3.9: Representative procedure for the synthesis of 2, 4-diamino-6-chloropyrimidines (31-
33) 
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4 4
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Reagents and conditions: a) dioxane, DIPEA, stirring 65 hours for 31, 90 hours for 32 at 100 ˚C, 
evaporation, extraction, column chromatography; or b) dioxane, 37% HCl, stirring 140 hours for 33 
at 100 ˚C, evaporation, extraction, column chromatography using DCM: hexane (90:10; v:v). 
 
3.1.2.5. Synthesis of 4-[4-chloro-6-(4-fluorophenylamino)-pyrimidin-2-yl]-piperazin-1-yl}    
phenylmethanone {MY12 (35)}, {4-[2-(4-benzamidylpiperazin-1-yl)-6-chloro-pyrimidin-4-yl]-
piperazin-1-yl}-phenyl-methanone MY15 (38)  
The first step in preparing these compounds is to cleave the protecting group BOC. The aim of 
using boc piperazine as a substituent is to prepare new piperazine derivatives that are not 
commercially available and so to get diversity in the resulted compounds. Compound (34) with one 
protecting group BOC at C2-position was treated under acidic conditions to afford the amine free 
form of piperazinylpyrimidine as white salt (34), this salt was then treated with as depicted in 
[Scheme 3.10] under basic conditions with benzoyl chloride to produce (35) with  
benzoylamidylpiperazine substitutent at C2-position  as a light brown powder in yield around 47%. 
(35) was characterized by 
1
H-NMR, FT-IR and ESI-MS spectroscopy. (38) Was prepared by 
cleaving the BOC protecting groups at 2 and 4-position in the symmetrical 2,4-diaminopyrimidine 
(36) under acidic conditions to get MY14 (37) as hydrochloride salt. (37) was treatted with 2 
equivalents of benzoyl chloride (11) under basic conditions to form (38) with two benzamide 
piperazine derivatives at 2 and 4- position. The procedures depicted in [Scheme 3.10]. 
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Scheme 3.10: Representative procedure for the synthesis of (35) and (38): 
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Reagents and conditions: a) EtOH, HCl(aq), stirring 6 hours, cooling, filtration, b) Pyridine, 
DIPEA, reflux 48 hours extraction and evaporation of solvent. c) Pyridine, TEA, reflux 22 hours 
extraction and evaporation of solvent. 
  
3.1.3. Step-3: Synthesis of 2,4,6-trisubstitutedpyrimidines  
This is the third and last step in preparing 2,4,6-tisubstituted pyrimidines. This step takes place by 
attacking the chlorine atom at the 6-position. After the occupation of the 2 and 4 positions of 
pyrimidine core with an amino groups, the attacking of the third chlorine in 2,4-diamino-6-
chloropyrimidine compounds becomes more difficult due to the highest deactivation of the chlorine 
atom and so vigorous reaction are required for this replacement step. The 2, 4-diamino-6-
chloropyrimidine compounds from the second step of substitution that discussed above are used as 
starting material and reacted either with amines or alkoxides. The result of this reaction is 
displacement of chloro group at position 6 of pyrimidine core with a new moiety. A further 
purification is still needed to afford a pure 2,4,6-trichloropyrimidies [Scheme 3.11]. 
Scheme 3.11:-General strategy for the synthesis of 2,4,6-trichloropyrimidine derivatives. 
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NN
Cl X1
X2
2, 4-diamino-6-chloro
pyrimidin
NN
X3 X1
X2
2, 4, 6 -trichloropyrimidin
a)
 
Reagents and conditions: a) solvent, reflux hours, extraction and evaporation of solvent and re-
crystallization. 
 
3.1.3.1. Synthesis of 6-ethoxy-N2,N4-bis(4-(trifluoromethoxy)phenyl)pyrimidine-2,4-diamine 
{MER1(39)}  
The starting reagent that used in this reaction was a symmetrical 2,4-diamino compound MY1 (24). 
Ethanol is also used as reagent and solvent. This reaction includes the displacement of chlorine 
atom at 6-position by ethoxide group (CH3CH2O
-
). By reacting ethanol with sodium metal a sodium 
ethoxide is formed in situ and acts as nucleophile to make a nucleophilic attack on the carbon 
carrying the third chlorine atom. 1.2 moles of sodium is used per mole of 2,4-diamino-6-
chloropyrimidine. The reaction of compound (39) took about 90 hours and obtained in 75% yield. 
The procedure of the compound depicted in [Scheme 3.12]. 
 
Scheme 3.12: Representative procedure for the synthesis of 39: 
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Reagents and conditions: a) EtOH, Sodium metal, stirring 90 hours for (39), extraction, and 
evaporation. 
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3.1.3.2. Synthesis of {4-[4-(4-Benzoylpiperazin-1-yl)-6-(2-hydroxyethylamino)-pyrimidin-2-
yl]-piperazin-1-yl}-phenylmethanone MRE8 (46) 
The starting reagent that used in this reaction is also a symmetrical 2,4-diamino compound MY15 
(38) that previously  prepared. The reaction was performed in dioxane under basic conditions using 
K2CO3 by using ethanolamine (12) as a substituent for replacing the third chlorine atom at the 6-
position, the reaction undergo nucleophilic substitution. Extraction and the re-crystallization were 
performed to purify the 2,4,6-triaminopyrimidine compound (46) with a yield 33%. The procedure 
of prepared compound depicted in [Scheme 3. 13] below.  
Scheme 3.13: Representative procedure for the synthesis of {4-[4-(4-Benzoylpiperazin-1-yl)-6-(2-
hydroxyethylamino)-pyrimidin-2-yl]-piperazin-1-yl}-phenylmethanone (46) 
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 Reagents and conditions: a) K2CO3, dioxane, stirring at reflux 100 ˚C for 25 hours, extraction. 
 
3.1.3.3. Synthesis of 2,4,6-trisubstituted analogues (41-43) 
Asymmetric 2,4,6-trisubstituted analogues (41), (43), (44) were synthesized using the intermediates 
(28), (30), (27) respectively. Phenol was converted into a nucleophilic form with sodium metal in 
dried THF; a sodium phenoxide is formed in situ and acts as nucleophile to make a nucleophilic 
attack on the carbon carrying the third chlorine atom. Extraction and re-crystallization performed to 
purify the compounds (41), (42), (43) with a yield 29%, 33%, 21% respectively. The procedures of 
the three compounds depicted in [Scheme 3.14] below. 
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Scheme 3.14: Representative procedure for the synthesis of (42, 43, and 44): 
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Reagents and conditions: a) phenol, sodium metal, THF dry. Stirring at reflux for about 100-120 
hours, extraction, and re-crystallization using hexane. 
 
3.1.3.4. Synthesis 2,4,6-triamiopyrimidine derivatives of (44-45) 
In these reactions 4-fluroaniline (2) was used as a substituent for replacing the third chlorine atom at 
the 6- position, the reactions undergo nucleophilic attack substitution under acidic conditions using 
37% HCl. The precursors (29), (30) were used as precursors to give the 2,4,6-triaminopyrimidine 
compounds (44), (45) in 20%, 26% yield respectively [Scheme 3.15]. The reactions were stirred at 
reflux for 40-48 hours until the completion.  
Scheme 3.15: Representative procedure for the synthesis of (44) and (45)  
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Reagents and conditions: a) 37% HCl, dioxane, stirring at reflux  at 100 ˚C for 40 hours for 
(44),48 hours for (45), extraction, re-crystallization.  
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Conclusion of the Synthetic Chemistry Part  
 
Disubstituted pyrimidine derivatives 
 
A set of 15 compounds of 2,4-diaminosubstituted pyrimidines were  prepared through this research. 
Three of them are symmetrical derivatives (Figure 3.1(a) and the other 12 are asymmetrical 
(Figure 3.1 (b). All these newly synthesized compounds were purified and characterized and some 
of them were tested for their biological activity.  
 Figure 3.1 : Disubstituted pyrimidine Derivatives (a) Symmetrical Disubstituted Pyrimidines 
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 (b) Asymmetrical Disubstituted Pyrimidines Derivatives 
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Trisubstituted pyrimidine derivatives 
 
A set of 7 compounds of 2,4,6-trisubstituted pyrimidines were prepared through this research as a 
final compounds. Four of them are with alkoxide substituent at 6-position (Figure 3.2(a)) and the 
other three are with amino group at 6-position (Figure 3.2 (b)). All of these newly synthesized 
compounds were purified and some of them are still need more characterization. 
Figure 3.2: 2,4,6-Trisubstituted pyrimidine Derivatives 
 
a) 2,4,6-trisubstituted pyrimidines with alkoxide substituent at 6-position (39, 41,42,43) 
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b) 2,4,6-trisubstituted pyrimidines with amine substituent at 6-position (44, 45, 46) 
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3.2. Biological Activity of the Synthesized compounds  
The main aim of the study is to synthesize 2,4,6-trisubstituted pyrimidine derivatives to act as 
Coactivator Binding Inhibitors (CBIs) for estrogen receptor signaling as a alternative approach  for 
breast cancer treatment. However, intermediates that were synthesized down the road toward 2,4,6-
trisubstituted derivatives  i.e. 2,4-diamiopyrimidines were assessed for their biological activity 
against Acute Myeloid Leukemia (AML ). The rationale behind this was our awareness that 2,4-
disubstituted pyrimidines were known as potential kinase inhibitors. Aggressive AML is known as 
FLT3-ITD [FMS-like tyrosine kinase 3) internal tandem duplication (ITD)) receptor tyrosine kinase   
mutant driven.  Hence the decision to evaluate the activity of the synthesized compounds in Acute 
Monocytic Leukemia (AML) cells.  
In vitro Assessment of Cellular Activity in Acute Myeloid Leukemia (AML) Cell Line: 
To evaluate the cellular activity of the synthesized compounds, acute monocytic leukemia (Molm-
13) cell line were used. This cell line had been stably transfected by sh-RNA (empty vector) and sh-
p53 RNA (sh-p53). (shRNA) a short hairpin RNA is an RNA sequence that can be engineered to 
suppress the expression of desired genes via RNA interference (RNAi).
 [130]
  shRNAs have been 
often applied for in vivo gene silencing. They have been delivered using viral vectors or being 
directly injected into fertilized oocytes for making transgenic mice 
[131]
 
 (Molm-13 shp-53) are p53 knocked down Molm-13 cells that generated by retroviral transfection 
for stable expression of shRNA against p53 using the pRETRO SUPER-p53 vector. p53 is a gene 
that produces a protein, called p53 protein that can detect abnormal cells, and then start to kill them 
to prevent their reproduction, therefore preventing tumor formation.
 [132, 133]
 p53 a tumor suppressor 
gene in a wide spectrum of human cancers that is  frequently mutated in up to 50% of breast, colon, 
lung, liver, prostate, bladder, and skin cancer. Most of these mutations end are defined as  loss of 
function of p53.
[134]
 For the biological assessment of the inhibitory effect of the synthesized 
compounds Molm-13 cell lines were used.  
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To evaluate the role of p53 in growth inhibition two forms of Molm-13 cells were used. In one case 
cells were transfected time with empty vector and in the other the needed concentration of the 
relevant compound was added to cells tranfected with sh-p53 RNA (sh-p53). The viability of the 
cells was determined using WST-1 assay. (Figure 3.3) below shows the nuclear staining using this 
assay for compound MY3 (26).    
 
Figure 3.3: A) nuclear staining of HL60 cells using WST-1 assay after treatment with 10μM of 
MY3 (26) for 24 hours; B) nuclear staining of Molm-13 cells using WST-1 assay after treatment 
with 10μM of MY3 (26) for 24 hour. 
 
Molm-13 growth Inhibition and SAR Studies 
The structure-activity relationship (SAR) that could be drawn from the (IC50 values, Table 3.1)  
Indicated that the potency was sensitive to steric and electronic factors of the substituent residing at  
C-2 and C-4 positions of the central pyrimidine ring. The tested compounds have show weak to 
moderate activity against Molm-13 (empty vector) [IC50 = 8.3 to 33.7 μM] and Molm-13 (sh-p53) 
[IC50 = 9.3 to 24.83 μM]. Compound (35) was relatively more potent than others with IC50 (8.3 μM 
and 9.3 μM respectively) while (38) is the least potent with IC50 (33.57 μM and 24.83 μM).  
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Figure 3.4: IC50 values for the compounds (M3 (17), MY1 (24), MY3 (26), MY4 (27), MY5 (28), 
MY6 (29), MY12 (35), and MY15 (38)) in Molm-13 cell line. 
 
 
Table 3.1: Structural activity relationship and IC50 values of the compounds (17, 24, 25, 26, 27, 28, 
29, 35, and 38) 
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(in μM )IC50    
Molm-13 
(empty vector) 
(in μM   )IC50 
Molm-13 
(sh-p53) 
41 M3 
 
24.27 22.18 
44 MY1 
 
13.61 16.18 
44 MY2 
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44 MY3 
 
41 
 (not tested in 
this cell type) 
41 MY4 
 
44.41 14.25 
42 MY5 
 
12.28 11.58 
43 MY6 
 
14.48 10.23 
94 MY12 
 
2.9 9.3 
92 MY15 
 
99.14 24.83 
NA = Not active 
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The activity of the compound MY3 (26) was evaluated against two cell lines. The first is the Molm-
13 and the second was HL-60 (human promyelocytic leukemia cells). The second cell line was 
derived from a 36-year-old woman with acute promyelocytic leukemia at the National Cancer 
Institute and is predominantly a neutrophilic promyelocyte (precursor). Results have showed that 
the IC50 of the MY3 (26) was 10 μM in the Molm-13 and was 10.3 μM in HL-60 cells. These 
results indicate that MY3 (26) exerts similar activity in the both cell lines and that p53 not involved 
in the mechanism of action of MY3 (26). From the graph shown in (Figure 3.5) a dose dependent 
effect of MY3 (26) was noticed that as the concentration of MY3 (26) increased the viability of the 
cells decreases. Molm-13 cells were treated for 24 hour at 10 µM concentration and viability of the 
cells was determined using WST-1 assay. The nuclear staining results revealed that the dye 
intensity decreases in the cells that subjected to 10 µM of MY3 (26) (Figure 3.3) indicating that 
this compound has an inhibition activity on the cells. 
 
Figure 3.5: Concentration-response effect of M3 (17), MY1 (24) and MY2 (25), MY3 (26) on 
cancer cell culture: cell viability was measured by WST-1assay. Data are expressed as the 
mean ± SD of two independent experiments. 
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To understand the effect of character of the substituent and the position on the pyrimidine core the 
IC50 of MY3 (26) was compared to other derivatives. The compound MY3 (26) with a 4-
trifluromethoxyaniline group at 4-position and with 1-(5-trifluoromethyl-pyridin-2-yl)-piperazine at 
2-position have a moderate IC50 values about 10 μM. To identify which among the two substituents 
(trifluromethoxyaniline or 1-(5-trifluoromethyl-pyridin-2-yl)-piperazine) is more important for the 
activity the symmetrical analogues were synthesized. When the 2- and 4-position of pyrimidine 
were substituted, with 4-trifluromethoxyaniline group in MY1 (24) the compound still have a 
moderate potency with IC50 13 μΜ but lower than MY3 (26) (Figure 3.5). The presence of the two 
4-trifluromethoxyaniline groups decrease the activity than in the case of using one group of 4-
trifluromethoxyaniline in MY3 (26). When the 2- and 4-positions of pyrimidine were substituted 
with 1-(5-trifluoromethyl-pyridin-2-yl)-piperazine, the resulted compound MY2 (25) showed a 
highly drop in the potency and no significant inhibition had been noticed. This result confirms the 
importance of presence of one trifluromethoxyaniline group on the pyrimidine core where when the 
trifluromethoxy was excluded from the compound MY2 (25) the potency decreesed  in a 
remarkable values (Figure 3.5). Comparision between the structures and the potency of these three 
compounds (MY3 (26), MY1 (24), MY2 (25)) emphasize that the 4-trifluromethoxyaniline should 
be maintained as a substituents  at 4- positions and that the variation should include the substitutions 
at 2-position. After showing the selective importance of at least one trifluromethoxyaniline at 4- 
position of the pyrimidine ring, we wanted to probe the ability of other piperazine derivatives at 2-
position to affect the potency 
To develop a structure–activity relationship (SAR) around the compound MY3 (26). A series of 
MY3 analogues had been synthesized by keeping the 4-pyrimidine substitution pattern with the 
trifluoromethoxyaniline group, and adding several structural moieties at the C-2 of the pyrimidine 
ring using different piperazinyl-derivatives. The analogues have been synthesized, purified using 
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chromatography techniques, characterized by 
1
H-NMR. Three of these analogues had been 
biologically tested and investigated for having activity on Molm-13 cancer cells. Results of the 
tested compounds demonstrated that compounds containing phenyl piperazine such as MY4 (27), 1-
4 pyridypiperazine such as MY5 (28), 1-(3-trifluoromethyl-pyridin-2-yl)-piperazine such as MY6 
(29) at the 2-position of the pyrimidine ring exhibit moderate biological activity. MY4 (27) have 
lower potency than MY3 (26). It differs from MY3 (26) in having phenyl ring instead of pyridine 
ring with attached CF3 group to the ring. The compounds MY5 (28) and MY6 (29) have a lower 
potency than MY4 (27). These two compounds contain N-heteroaromatic ring (pyridine ring). It 
became evident that there is a necessary relationship between the presence of N-heteroaromatic ring 
attached to the piperazine ring and the potency, where the potency decreased in the case of N-
heteroaromatic ring compared with the case of phenyl ring. We rationalized that the importance of 
the phenyl ring was most likely based on its ability to make a hydrophobic interaction and fit deeply 
in the pocket while the N-heteroatom has the ability to act as a hydrogen-bond donor. Compound 
MY6 (29) which exactly contains the same substituent groups that present in MY3 (26) but with a 
small structural changes of the CF3 substituents on the N-heteroaromatic ring at 3-position instead 
of 5-position in MY3 (26). This small difference of branched CF3 position had influenced the 
binding affinities and potency of this compound. (Figure 3.6) 
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Figure 3.6: Concentration-response effect of MY4 (27), MY5 (28) and MY6 (29) on cancer cell 
culture: cell viability was measured by WST-1assay. Data are expressed as the mean ± SD of two 
independent experiments. 
 
The compound MY12 (35) with a 4-fluroaniline group at 4-position and with benzoylpiperazine at 
2-position have the best IC50 values about 8.3 μM. Comparision of activities of this compound with 
the activity of compound MY15 (38) containing two benzoylpiperazine groups at the 2-and 4- 
positions with IC50 Value of 33.75 μM indicated that only one N4-benzoylpiperzinyl- group at 2-
position was the causative part of potency increasing and recommended to  be retained in future 
studies (Figure 3.7) 
The amide bridge in MY12 (35) make this compound the most potent one of all compounds 
containing piperazine derivatives. This bridge  might gave the suitable distance for making a 
hydrogen bond interaction which not allowed in other compounds although they have N-heteroatom 
and have the ability to make hydrogen bound. 
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Figure 3.7: Concentration-response effect of MY12 (35), MY15 (38) on cancer cell culture: cell 
viability was measured by WST-1assay. Data are expressed as the mean ± SD of two independent 
experiments. 
 
The graph inserted below (Figure 3.8) showed that at the concentration 1μM  MY5 (28) was the 
most active compound while MY4 was the lowest active compound. In other hand the compound 
MY4(27) showed the highest activity at the concentration 31.6 μM with 1% cell viablility while the 
compound MY15 showed the lowest activity with a 89% cell viability. All the compounds inserted 
in the graph have a dose dependent effect in killing Molm-13 empty vector cells with the 
concentration range (31.6μ -100 μ). The compound MY15 (36) was the less potent compound of the 
tested compoundes while the compound MY2 (25) had no significant inhibtion  and had poor effect 
in killing and inhibition the cancer cells growth, in other words it was noticed that even at high 
concentrations (100 μ) the compound seems not working and the cell viability still high. Of all these 
compounds MY12 (35) was the potent one. 
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Figure 3.8: Cell vialbilty response of Molm-13 empty vector  at different concentrations (1 μM, 
3.16 μM,10 μM ,31.6 μM ,100 μM) of different compounds (M3, MY1, MY2, MY4, MY5, MY6, 
MY12, MY15). 
 
On (Molm-13 sh-p53) cells, all tested compounds had shown similar activities to those against in 
Molm-13 empty vector cells (Figure 3.9). In some cases the inactivation of this gene can cause 
cancer development or other diseases. In acute myeloid leukemia (AML), p53 mutations have been 
detected in only about 5% of patients, but mutation is recognized as an adverse factor for response 
to chemotherapy and prognosis. These results demonsrated that the mechanism of action of the 
tested compounds didn’t  depend on the p53 pathway to exert their inhibition activity on the tested 
cells. 
 
 
Figure 3.9: Cell vialbilty response of Molm-13 sh-p53 at different concentrations (1 μM, 3.16 μM, 
10 μM ,31.6 μM ,100 μM ) of different compounds (M3, MY1, MY2, MY4, MY5, MY6, MY12 , 
MY15). 
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3.3. Computational Chemistry  
 
The PASS (Prediction of Activity Spectra for Substances) software had been used to predict 
the pharmacological effects and biochemical mechanisms of the newly synthesized compounds on 
the basis of the structural formula of a substance. (Table 3.2) shows the predicted activity of 
some compounds. 
Table 3.2: Biological activity spectrum of compound predicted on the basis of SAR 
 
Number 
  
Code Compound Structure Mol.    
Mass 
Expected activity 
17 M3 
 
 
324.09 
-Analagesic, non opioid 
- Antineoplastic (nonhodgkin’s  
lymphoma) 
- Antineoplastic (multiple 
myeloma) 
- Antipsoriatic 
-Vasculitis treatment 
 
 
 
 
24 
 
 
 
 
MY1 
 
464.75 
 -Signal transduction pathway 
inhibitor 
  - Angiogenesis inhibitor 
-Antieczematic atopic 
Antineoplastic 
Transplant rejection treatment 
 
 
 
 
 
 
25 
 
 
 
 
 
MY2 
  
 
 
 
 
572.94 
-Hematopotic inhibitor 
-Antiasthmatic 
Antineoplastic (nonhodgkin’s  
lymphoma) 
- Transplant rejection treatment 
-Anxiolytic 
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26 
  
 
 
 
 
MY3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
518 
-Antineurogenic pain 
-analagesic, non opioid 
-autoimmune disorders 
treatment 
- Transplant rejection treatment 
- Atherosclerosis teatment 
 
 
 
 
27 
 
 
 
 
MY4 
 
 
 
 
 
 
 
 
 
 
 
449.86 
 
 
Antieczematic atopic 
- Antineurogenic 
-Transplant rejection treatment 
-Scleroderma treatment 
-Analagesic, non opioid 
 
 
 
 
 
28 
 
 
 
 
 
MY5 
 
 
 
 
 
 
 
 
 
 
 
 
 
450.84 
 
 
- Signal transduction pathway 
inhibitor 
- Transplant rejection 
treatment. 
-Antieczematic atopic 
-Antineurogenic 
  
 
 
 
 
 
 
29 
 
 
 
 
 
 
MY6 
  
 
 
 
 
 
518.84 
 
 
 
-Analagesic, non opioid 
-Antineurogenic pain 
-Atherosclerosis teatment 
-Autoimmune disorders 
treatment 
- Transplant rejection treatment 
 
 
 
 
 
30 
 
 
 
 
MY7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
451 
-Glycogen synthase stimulant 
- Nav1.6 sodium channel 
blocker 
-Tyrosine-protein kinase BMX 
inhibitor 
-potassium channel small-
conductance Ca-activated 
blocker 
signal transduction pathways 
inhibitor 
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35 
 
 
 
 
 
MY12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
411.86 
 
 
 
-Antieczematic atopic 
-Transplant rejection treatment. 
-A nalagesic, non opioid 
-Hematopotic inhibitor 
-Scleroderma treatment 
 
 
 
 
 
 
38 
 
 
 
 
 
 
MY15 
  
 
 
 
 
491 
-A nalagesic, non opioid 
-Hematopotic inhibitor 
-Scleroderma treatment 
- Antieczematic atopic 
-Transplant rejection treatment 
 
 
 
 
 
 
 
39 
 
 
 
 
MER 1 
  
 
 
 
474 
 
 
-signal transduction pathways 
inhibitor 
-Tyrosine-protein kinase BMX 
inhibitor 
-angiogenesis inhibitor 
- dihydroorotase inhibitor 
 
 
 
 
41 
 
 
 
 
MER3 
 
 
 
 
 
 
 
 
509 
- signal transduction pathways 
inhibitor 
- Nav1.6 sodium channel 
blocker 
-Tyrosine-protein kinase BMX 
inhibitor 
-Glycogen synthase stimulant 
 
 
42 
 
 
MER4 
  
 
507 
- signal transduction pathways 
inhibitor 
-Tyrosine-protein kinase BMX 
inhibitor 
- Nav1.6 sodium channel 
blocker 
-CC chemokine 6 receptor 
antagonist  
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43 
 
 
 
MER5 
  
 
 
508 
- signal transduction pathways 
inhibitor 
-Tyrosine-protein kinase BMX 
inhibitor 
- Nav1.6 sodium channel 
blocker 
-Angiogenesis inhibitor 
-glycogen synthase stimulant 
 
 
 
44 
 
 
 
MER6 
  
 
 
594 
-Vaniloid antagonist 
- Tyrosine-protein kinase BMX 
inhibitor 
- Nav1.6 sodium channel 
blocker 
- signal transduction pathways 
inhibitor 
 
 
 
45 
 
 
 
MER7 
  
 
 
526 
-Nav1.6 sodium channel 
blocker 
- signal transduction pathways 
inhibitor 
- Tyrosine-protein kinase BMX 
inhibitor 
- protein kinase inhibitor 
-glycogen synthase stimulant 
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Conclusion 
This research project focuses on synthesizing small molecules that mimetic nuclear hormone 
receptor of (NR) co-activator proteins with special focus on the estrogen receptor alpha (ERα).Such 
molecules that distrup the (ER)/coactivator proteins may provide an alternative mechanism for 
blocking estrogen signaling and activity in breast cancer.  
The compounds prepared in the current study were done through sequential substitution of the 
chlorides of 2,4,6-trichloropyrimidine by nucleophiles like amines, alkoxides or aryloxides. The 
synthesized compounds were purified using chromatography techniques, and characterized by (
1
H-
NMR, 
13
C-NMR, FT-IR spectroscopy and ESI-MS spectrometry. Some of these compounds were 
screened for their inhibitory activity against the acute myeloid leukemia cells (Molm-13) cells. The 
viability of the cells was determined using WST-1 assay. 
 Initial  in vitro results of few tested compounds demonstrated that (35) and (26) exhibited moderate 
activities against the two forms of Molm-13 cell lines and have a dose dependent response while 
compound (25) showed no significant inhibitory action on the same cell lines. 
 
 
 
 
 
 
 
 
 
 
 
 
 98 
 
 
 
 
 
 
 
 
 
 
Chapter Five 
 
Refrences 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 99 
 
Refrences: 
1.  Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2015. CA Cancer J Clin, 2015. 
65(1): p. 5-29. 
2.  Blows, F.M., et al., Subtyping of breast cancer by immunohistochemistry to investigate a 
relationship between subtype and short and long term survival: a collaborative analysis of 
data for 10,159 cases from 12 studies. PLoS Med, 2010. 7(5): p. e1000279. 
0.  DeSantis, C., et al., Breast cancer statistics, 2013. CA Cancer J Clin, 2014. 64(1): p. 52-
62. 
8.  Hicks, D.G. and R.R. Tubbs, Assessment of the HER2 status in breast cancer by 
fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum 
Pathol, 2005. 36(3): p. 250-61. 
5.  Fackenthal, J.D. and O.I. Olopade, Breast cancer risk associated with BRCA1 and BRCA2 
in diverse populations. Nature Reviews Cancer, 2007. 7(12): p. 937-948. 
7.  Filippini, S.E. and A. Vega, Breast cancer genes: beyond BRCA1 and BRCA2. Front 
Biosci (Landmark Ed), 2013. 18: p. 1358-72. 
6.  Economopoulou, P., G. Dimitriadis, and A. Psyrri, Beyond BRCA :new hereditary breast 
cancer susceptibility genes. Cancer Treat Rev, 2015. 41(1): p. 1-8. 
4.  Bai, Z. and R. Gust, Breast cancer, estrogen receptor and ligands. Archiv der Pharmazie, 
2009. 342(3): p. 133-149. 
2.  Lonard, D.M., R. Kumar, and B.W. O'Malley, Minireview: the SRC family of coactivators: 
an entree to understanding a subset of polygenic diseases? Mol Endocrinol, 2010. 24(2): p. 
279-85. 
10.  Mokbel, K., The evolving role of aromatase inhibitors in breast cancer. International 
journal of clinical oncology, 2002. 7(5): p. 0279-0283. 
11.  Dowsett, M., Overexpression of HER-2 as a resistance mechanism to hormonal therapy 
for breast cancer. Endocrine-related cancer, 2001. 8(3): p. 191-195. 
12.  Lumachi, F., et al., Treatment of estrogen receptor-positive breast cancer. Current 
medicinal chemistry, 2013. 20(5): p. 596-604. 
10.  Higgins, M.J. and J. Baselga, Targeted therapies for breast cancer. The Journal of clinical 
investigation, 2011. 121(10): p. 3797. 
18.  Schiff, R., et al., Breast cancer endocrine resistance: how growth factor signaling and 
estrogen receptor coregulators modulate response. Clin Cancer Res, 2003. 9(1 Pt 2): p. 
447S-54S. 
 111 
 
15.  Kaur, R., et al., Anti-cancer pyrimidines in diverse scaffolds: a review of patent literature. 
Recent Pat Anticancer Drug Discov, 2015. 10(1): p. 23-71. 
17.  Bridgham, J.T., et al., Protein evolution by molecular tinkering: diversification of the 
nuclear receptor superfamily from a ligand-dependent ancestor. PLoS biology, 2010. 
8(10): p. 2551. 
16.  LaFrate, A., Synthesis and Biological Evaluation of Coactivator Binding Inhibitors and 
Bivalent Ligands for the Estrogen Receptor2008: ProQuest. 
14.  Miller, T.W., J.M. Balko, and C.L. Arteaga, Phosphatidylinositol 3-kinase and 
antiestrogen resistance in breast cancer. Journal of Clinical Oncology, 2011. 29(33): p. 
4452-4461. 
12.  Rodriguez, A.L., et al., Design, synthesis, and in vitro biological evaluation of small 
molecule inhibitors of estrogen receptor alpha coactivator binding. J Med Chem, 2004. 
47(3): p. 600-11. 
20.  Selvam, T.P., et al., A mini review of pyrimidine and fused pyrimidine marketed drugs. Res 
Pharm, 2012. 2: p. 1-10. 
21.  Dudhe, R., et al., Pyrimidine as anticancer agent: a review. Journal of Advanced Scientific 
Research, 2011. 2(3): p. 10-17. 
22.  Modi, V.S .and T.S. Basuri, The Physiological and Medicinal Potential Pyrimidines & 
Different Scheme to Synthesize Pyrimidine Heterocycles. ChemInform, 2012. 43(14.) 
20.  Jain, K., et al., Biological and medicinal significance of pyrimidines. CURRENT 
SCIENCE-BANGALORE-, 2006. 90(6): p. 793. 
28.  Kumar, N., A. Chauhan, and S. Drabu, Synthesis of cyanopyridine and pyrimidine 
analogues as new anti-inflammatory and antimicrobial agents. Biomed Pharmacother, 
2011. 65(5): p. 375-80. 
25.  Sharma, V., N. Chitranshi, and A.K .Agarwal, Significance and biological importance of 
pyrimidine in the microbial world. Int J Med Chem, 2014. 2014: p. 202784. 
27.  Zhou, W., et al., Antifolates as effective antimicrobial agents: new generations of 
trimethoprim analogs. MedChemComm, 2013. 4 (7 :) p. 908-915. 
26.  Cheng, Q. and S. Shapourifar-Tehrani, Comparative efficacy of antiviral drugs on human 
ocular fibroblasts. Ophthalmic Literature, 1996. 2(49): p. 90. 
24.  Summa, V., et al., 4,5-dihydroxypyrimidine carboxamides and N-alkyl-5-
hydroxypyrimidinone carboxamides are potent, selective HIV integrase inhibitors with 
 111 
 
good pharmacokinetic profiles in preclinical species. J Med Chem, 2006. 49(23): p. 6646-
9. 
22.  Muller, G.G., et al., Efficacy of an organic solvent and ultrasound for filling material 
removal. Braz Dent J, 2013. 24(6): p. 585-90. 
00.  Rastelli, G., et al., Interaction of pyrimethamine, cycloguanil, WR99210 and their 
analogues with Plasmodium falciparum dihydrofolate reductase: structural basis of 
antifolate resistance. Bioorg Med Chem, 2000. 8(5): p. 1117-28. 
01.  Sunduru, N., et al., Synthesis and antileishmanial activity of novel 2,4,6-trisubstituted 
pyrimidines and 1,3,5-triazines. Eur J Med Chem, 2009. 44(6): p. 2473-81. 
02.  Kurebayashi, Y., et al., Dulcerozine-induced duodenal ulcers in rats: a simple, highly-
reliable model for evaluating anti-ulcer agents. Arch Int Pharmacodyn Ther, 1984. 271(1): 
p. 155-68. 
00.  Ugale, V.G., et al., Quinazolino-benzothiazoles: fused pharmacophores as anticonvulsant 
agents. Eur J Med Chem, 2012  .50 : p. 107-13. 
08.  Sagi, V.N., et al., Synthesis and biological evaluation of novel pyrimidine derivatives as 
sub-micromolar affinity ligands of GalR2. Bioorg Med Chem Lett, 2011. 21(23): p. 7210-
5. 
05.  Sloop, K.W., et al., Novel small molecule glucagon-like peptide-1 receptor agonist 
stimulates insulin secretion in rodents and from human islets. Diabetes, 2010. 59(12): p. 
3099-3107. 
07.  Mizumoto, H. and A. Karasawa, Renal tubular site of action of KW-3902, a novel 
adenosine A1-receptor antagonist, in anesthetized rats. Jpn J Pharmacol, 1993. 61(3): p. 
251-3. 
06.  Fredholm, B.B., et al., International Union of Basic and Clinical Pharmacology. LXXXI. 
Nomenclature and classification of adenosine receptors—an update. Pharmacological 
reviews, 2011. 63(1): p. 1 -08.  
04.  van Muijlwijk-Koezen, J.E., et al., Isoquinoline and quinazoline urea analogues as 
antagonists for the human adenosine A3 receptor. Journal of medicinal chemistry, 2000. 
43(11): p. 2227-2238. 
02.  Chandrasekaran, S. and S. Nagarajan, Microwave-assisted synthesis and anti-bacterial 
activity of some 2-Amino-6-aryl-4-(2-thienyl) pyrimidines. Il Farmaco, 2005. 60(4): p. 279-
282. 
 112 
 
80.  Parker, W.B., Enzymology of purine and pyrimidine antimetabolites used in the treatment 
of cancer. Chemical reviews, 200 2 .102(6 :) p. 2880-2893. 
81.  Burchenal, J.H., et al., Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in 
the treatment of leukemia and allied diseases. Blood, 1953. 8(11): p. 965-999. 
82.  Al-Turkistani, A.B.A.A., P. Al-Deeb, and A. Omar, Synthesis of New Pyrimidine 
Derivatives as Potential Chemotherapeutic Agents. 2010. 
80.  Lane, H. and T. O'reilly, Combination of Mtor Inhibitor and Antipolate Compound, 2008, 
Google Patents. 
88.  Clark, R.F., et al., Pyrimidine inhibitors of kinase activity  ,2010 , Google Patents. 
85.  Mealing, S., et al., The relative efficacy of imatinib, dasatinib and nilotinib for newly 
diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis. Exp 
Hematol Oncol, 2013. 2(1): p. 5. 
87.  Mangelsdorf, D.J., et al., The nuclear receptor superfamily: the second decade. Cell, 1995. 
83(6): p. 835-839. 
86.  Maglich, J.M., et al., Comparison of complete nuclear receptor sets from the human, 
Caenorhabditis elegans and Drosophila genomes. Genome Biol, 2001. 2(8 :)p. 1-0029. 
84.  Aranda, A. and A. Pascual, Nuclear hormone receptors and gene expression. Physiological 
reviews, 2001. 81(3): p. 1269-1304. 
82.  Chawla, A., et al., Nuclear receptors and lipid physiology: opening the X-files. Science, 
2001. 294(5548): p  .1477-1460.  
50.  Ribeiro, A., et al., Hepatic nuclear factor-4, a key transcription factor at the crossroads 
between architecture and function of epithelia. Recent Patents on Endocrine, Metabolic & 
Immune Drug Discovery, 2007. 1(2): p. 166-175. 
51.  Pawlak ,M., P. Lefebvre, and B. Staels, General molecular biology and architecture of 
nuclear receptors. Current topics in medicinal chemistry, 2012. 12(6): p. 486. 
52.  Leo, C., H. Li, and J.D. Chen, Differential mechanisms of nuclear receptor regulation by 
receptor-associated coactivator 3. J Biol Chem, 2000. 275(8): p. 5976-82. 
50.  Claessens, F., et al., Selective DNA binding by the androgen receptor as a mechanism for 
hormone-specific gene regulation. The Journal of steroid biochemistry and molecular 
biology  ,2001 .67(1 :) p. 23-30. 
58.  Leo, C. and J.D. Chen, The SRC family of nuclear receptor coactivators. Gene, 2000. 
245(1): p. 1-11. 
 113 
 
55.  Kojetin, D.J. and T.P. Burris, Small molecule modulation of nuclear receptor 
conformational dynamics: implications for function and drug discovery. Mol Pharmacol, 
2013. 83(1): p. 1-8. 
57.  Yang, C., Q. Li, and Y. Li, Targeting nuclear receptors with marine natural products. Mar 
Drugs, 2014. 12(2): p. 601-35. 
56.  Huss, J.M. and D.P. Kelly, Nuclear receptor signaling and cardiac energetics. Circ Res, 
2004. 95(6): p. 568-78. 
54.  Katzenellenbogen, B.S., et al., Molecular mechanisms of estrogen action: selective ligands 
and receptor pharmacology. J Steroid Biochem Mol Biol, 2000. 74(5): p. 279-85. 
52.  Rowan, B.G. and B.W. O'Malley ,Progesterone receptor coactivators. Steroids, 2000. 
65(10-11): p. 545-9. 
70.  Tan, J.A., et al., Mechanism of androgen receptor corepression by CKbetaBP2/CRIF1, a 
multifunctional transcription factor coregulator expressed in prostate cancer. Mol Cell 
Endocrinol, 2014. 382(1): p. 302-13. 
71.  Whitfield, G.K., et al., Steroid hormone receptors: evolution, ligands, and molecular basis 
of biologic function. J Cell Biochem, 1999. Suppl 32-33: p. 110-22. 
72.  Hatoum, A., et al., Overexpression of retinoic acid receptors alpha and gamma into 
neoplastic epidermal cells causes retinoic acid-induced growth arrest and apoptosis. 
Carcinogenesis, 2001. 22(12): p. 1955-63. 
70.  Li, M., et al., The orphan nuclear receptor NR4A1 regulates transcription of key 
steroidogenic enzymes in ovarian theca cells. Mol Cell Endocrinol, 2010. 319(1-2): p. 39-
46. 
78.  Chinetti, G., J.C. Fruchart, and B. Staels, Peroxisome proliferator-activated receptors 
(PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. 
Inflamm Res, 2000. 49(10): p. 497-505. 
75.  Viennois, E., et al., Targeting liver X receptors in human health: deadlock or promising 
trail? Expert Opin Ther Targets, 2011. 15(2): p. 219-32. 
77.  Baranowski, M., Biological role of liver X receptors. J Physiol Pharmacol, 2008. 59(Suppl 
7): p. 31-55. 
76.  Fujimura, T., et al., Differential expression of estrogen‐related receptors β and γ (ERRβ 
and ERRγ) and their clinical significance in human prostate cancer. Cancer science, 2010. 
101(3): p. 646-651. 
 114 
 
74.  Park, J.-I., S.Y. Tsai, and M.-J. Tsai, Molecular mechanism of chicken ovalbumin upstream 
promoter-transcription factor (COUP-TF) actions. The Keio journal of medicine, 2003. 
52(3): p. 174-181. 
72.  Zhao, Y. and D. Bruemmer, NR4A orphan nuclear receptors transcriptional regulators of 
gene expression in metabolism and vascular biology. Arteriosclerosis, thrombosis, and 
vascular biology, 2010. 30(8): p. 1535-1541. 
60.  Mizusaki, H., et al., Dax-1 (dosage-sensitive sex reversal-adrenal hypoplasia congenita 
critical region on the X chromosome, gene 1) gene transcription is regulated by wnt4 in 
the female developing gonad. Molecular Endocrinology, 2003. 17(4): p. 507-519. 
61.  O'Malley, B.W., A. Malovannaya, and J. Qin, Minireview: nuclear receptor and 
coregulator proteomics—2012 and beyond. Molecular Endocrinology, 2012. 26(10): p. 
1646-1650. 
62.  Tsai, M.J. and B.W. O'Malley, Molecular mechanisms of action of steroid/thyroid receptor 
superfamily members. Annu Rev Biochem, 1994. 63: p. 451-86. 
60.  Dasgupta, S., D.M. Lonard, and B.W. O'Malley, Nuclear receptor coactivators: master 
regulators of human health and disease. Annu Rev Med, 2014. 65: p. 279-92. 
68.  York, B. and B.W. O'Malley, Steroid receptor coactivator (SRC) family: masters of 
systems biology. J Biol Chem, 2010. 285(50): p. 38743-50. 
65.  Puigserver, P., et al., Activation of PPARγ coactivator-1 through transcription factor 
docking. Science, 1999. 286(5443): p. 1368-1371. 
67.  Lonard, D.M., R.B. Lanz, and B.W. O'Malley, Nuclear receptor coregulators and human 
disease. Endocr Rev, 2007. 28(5): p. 575-87. 
66.  Xu, J., R.C. Wu, and B.W. O'Malley, Normal and cancer-related functions of the p160 
steroid receptor co-activator (SRC) family. Nat Rev Cancer, 2009. 9(9): p. 615-30. 
64.  Savkur, R. and T. Burris, The coactivator LXXLL nuclear receptor recognition motif. The 
journal of peptide research, 2004. 63(3): p. 207-212. 
62.  Gampe, R.T., et al., Structural basis for autorepression of retinoid X receptor by tetramer 
formation and the AF-2 helix. Genes Dev, 2000  .18(16 :) p. 2229-2241. 
40.  Bourguet, W., P. Germain, and H. Gronemeyer, Nuclear receptor ligand-binding domains: 
three-dimensional structures, molecular interactions and pharmacological implications. 
Trends Pharmacol Sci, 2000. 21(10): p. 381-8. 
 115 
 
41.  Moore ,T.W., C.G. Mayne, and J.A. Katzenellenbogen, Minireview: Not picking pockets: 
nuclear receptor alternate-site modulators (NRAMs). Molecular Endocrinology, 2010. 
24(4): p. 683-695. 
42.  Moore, N.L., et al., Multiple nuclear receptor signaling pathways mediate the actions of 
synthetic progestins in target cells. Mol Cell Endocrinol, 2012. 357(1-2): p. 60-70. 
40.  Celik, L., J.D.D. Lund, and B. Schiøtt, Conformational dynamics of the estrogen receptor 
α: molecular dynamics simulations of the influence of binding site structure on protein 
dynamics. Biochemistry, 2007. 46(7): p. 1743-1758. 
48.  Katzenellenbogen, B.S. and J.A. Katzenellenbogen, Estrogen receptor transcription and 
transactivation: Estrogen receptor alpha and estrogen receptor beta-regulation by 
selective estrogen receptor modulators and importance in breast cancer. Breast cancer 
research, 2000. 2(5): p. 335. 
45.  Mannhold, R., et al., Nuclear receptors as drug targets. Vol. 39. 2008: John Wiley & Sons. 
47.  Pearce, S.T. and V.C. Jordan, The biological role of estrogen receptors alpha and beta in 
cancer. Crit Rev Oncol Hematol, 2004. 50(1): p. 3-22. 
46.  Henderson, B.E. and H.S. Feigelson, Hormonal carcinogenesis. Carcinogenesis, 2000. 
21(3): p. 427-433. 
44.  Musgrove, E.A. and R.L. Sutherland, Biological determinants of endocrine resistance in 
breast cancer. Nat Rev Cancer, 2009. 9(9): p. 631-43. 
42.  Khan, S.A., et al., Estrogen receptor expression of benign breast epithelium and its 
association with breast cancer. Cancer Res, 1994. 54(4): p. 993-7. 
20.  McKeage, K., M.P. Curran, and G.L. Plosker, Fulvestrant. Drugs, 2004. 64(6): p. 633-648. 
21.  Wood, A.J., I.E. Smith, and M. Dowsett, Aromatase inhibitors in breast cancer. New 
England Journal of Medicine, 2003. 348(24): p. 2431-2442. 
22.  Zhao, M. and B .Ramaswamy, Mechanisms and therapeutic advances in the management 
of endocrine-resistant breast cancer. World journal of clinical oncology, 2014. 5(3): p. 
248. 
20.  Uchino, J., et al., Positive effect of tamoxifen as part of adjuvant chemo-endocrine therapy 
for breast cancer. Hokkaido Adjuvant Chemo-Endocrine Therapy for Breast Cancer Study 
Group. British journal of cancer, 1994. 69(4): p. 767. 
28.  Ring, A. and M. Dowsett, Mechanisms of tamoxifen resistance. Endocrine-related cancer, 
2004. 11(4): p. 643-654. 
 116 
 
25.  Normanno, N., et al., Mechanisms of endocrine resistance and novel therapeutic strategies 
in breast cancer. Endocrine-related cancer, 2005. 12(4): p. 721-747. 
27.  Osborne, C.K. and R. Schiff, Mechanisms of endocrine resistance in breast cancer. Annual 
review of medicine, 2011. 62: p. 233. 
26.  Dixon, J.M., Endocrine Resistance in Breast Cancer. New Journal of Science, 2014. 2014: 
p. 27. 
24.  Henke, B. and D. Heyer, Recent advances in estrogen receptor modulators. Current 
opinion in drug discovery   & development, 2005. 8(4): p. 437-448. 
22.  Moore, T.W. and J.A. Katzenellenbogen, Inhibitors of nuclear hormone 
receptor/coactivator interactions. Annual reports in medicinal chemistry, 2009. 44: p. 443-
457. 
100.  Xu, J., R.-C. Wu, and B.W. O'Malley, Normal and cancer-related functions of the p160 
steroid receptor co-activator (SRC) family. Nature Reviews Cancer, 2009. 9(9): p. 615-
630. 
101.  Shiau, A.K., et al., Structural characterization of a subtype-selective ligand reveals a novel 
mode of estrogen receptor antagonism. Nature Structural & Molecular Biology, 2002. 
9(5): p. 359-364. 
102.  Becerril, J. and A.D. Hamilton, Helix mimetics as inhibitors of the interaction of the 
estrogen receptor with coactivator peptides. Angew Chem Int Ed Engl, 2007. 46(24): p .
8861-0. 
100.  Rodriguez, A.L., et al., Design, synthesis, and in vitro biological evaluation of small 
molecule inhibitors of estrogen receptor α coactivator binding. J Med Chem, 2004. 47(3): 
p. 600-611. 
108.  Parent, A.A., J.R. Gunther, and J.A. Katzenellenbogen, Blocking estrogen signaling after 
the hormone: pyrimidine-core inhibitors of estrogen receptor-coactivator binding. J Med 
Chem, 2008. 51(20): p. 6512-30. 
105.  Leduc, A.-M., et al., Helix-stabilized cyclic peptides as selective inhibitors of steroid 
receptor–coactivator interactions. Proceedings of the National Academy of Sciences, 
2003. 100(20): p. 11273-11278. 
107.  Shao, D., et al., Identification of novel estrogen receptor α antagonists. The Journal of 
steroid biochemistry and molecular biology  ,2008 .44(8 :) p. 351-360. 
 117 
 
106.  LaFrate, A.L., et al., Synthesis and biological evaluation of guanylhydrazone coactivator 
binding inhibitors for the estrogen receptor. Bioorganic & medicinal chemistry, 2008. 
16(23): p. 10075-10084. 
104.  Zhou, H.-B., et al . , Bicyclo [2.2. 2] octanes: close structural mimics of the nuclear 
receptor-binding motif of steroid receptor coactivators. Bioorg Med Chem Lett, 2007. 
17(15): p. 4118-4122. 
102.  Williams, A.B., et al., Synthesis of biphenyl proteomimetics as estrogen receptor-α 
coactivator binding inhibitors. Org Lett, 2009. 11(23): p. 5370-5373. 
110.  Chatterjee, B., The role of the androgen receptor in the development of prostatic 
hyperplasia and prostate cancer. Mol Cell Biochem, 2003. 253(1-2): p. 89-101. 
111.  Gunther ,J.R., et al., Amphipathic benzenes are designed inhibitors of the estrogen receptor 
alpha/steroid receptor coactivator interaction. ACS Chem Biol, 2008. 3(5): p. 282-6. 
112.  Taplin, M.E., Drug insight: role of the androgen receptor in the development and 
progression of prostate cancer. Nat Clin Pract Oncol, 2007. 4(4): p. 236-44. 
110.  Chmelar, R., et al., Androgen receptor coregulators and their involvement in the 
development and progression of prostate cancer. Int J Cancer, 2007. 120(4): p. 719-33. 
118.  Gunther, J.R., A.A. Parent, and J.A. Katzenellenbogen, Alternative inhibition of androgen 
receptor signaling: peptidomimetic pyrimidines as direct androgen receptor/coactivator 
disruptors. ACS Chem Biol, 2009. 4(6): p. 435-40. 
115.  Poroikov, V. and D. Filimonov, Computer-aided prediction of biological activity spectra. 
Application for finding and optimization of new leads. Rational Approaches to Drug 
Design, 2001: p. 403-407. 
117.  Filimonov, D. and V. Poroikov, PASS: Computerized prediction of biological activity 
spectra for chemical substances. Bioactive Compound Design: Possibilities for Industrial 
Use, 1996: p. 47-56. 
116.  Filimonov, D.A., et al., [The computerized prediction of the spectrum of biological activity 
of chemical compounds by their structural formula: the PASS system. Prediction of 
Activity Spectra for Substance]. Eksp Klin Farmakol, 1995. 58(2): p. 56-62. 
114.  Burov, Y.V., V. Poroikov, and L. Korolchenko, National system for registration and 
biological testing of chemical compounds: facilities for new drugs search. Bull. Natl. 
Center for Biologically Active Compounds (Rus.), 1990. 1: p. 4-25. 
 118 
 
112.  Avidon, V., The criteria of chemical structures similarity and the principles for design of 
description language for chemical information processing of biologically active 
compounds. Chim.-Pharm. J.(Rus), 1974. 8: p. 22-25. 
120.  Poroikov, V., et al., Robustness of biological activity spectra predicting by computer 
program PASS for noncongeneric sets of chemical compounds. Journal of chemical 
information and computer sciences, 2000. 40(6): p. 1349-1355. 
121.  De Britto, A.J., T. Raj, and D.A. Chelliah, Prediction of biological activity spectra for few 
anticancer drugs derived from plant sources. Ethnobotanical Leaflets, 2008. 2008(1): p. 
109. 
122.  Matsuo, Y., et al., Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and 
MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting 
from an occult chromosome insertion, ins (11; 9)(q23; p22p23). Leukemia, 1997. 11(9 :)p. 
1469-1477. 
120.  Varambally, S., et al., The polycomb group protein EZH2 is involved in progression of 
prostate cancer. Nature, 2002. 419(6907): p. 624-629. 
128.  Moore, G.E., R.E. Gerner, and H.A. Franklin, Culture of normal human leukocytes. 
JAMA, 196 6 .122(4 :) p. 519-24. 
125.  Parks, E.L., et al., Perhalogenated pyrimidine scaffolds. Reactions of 5-chloro-2,4,6-
trifluoropyrimidine with nitrogen centred nucleophiles. Beilstein J Org Chem, 2008. 4: p. 
22. 
127.  Baiazitov, R., et al., paper Chemoselective Reactions of 4, 6-Dichloro-2-(methylsulfonyl) 
pyrimidine and Related Electrophiles with Amines. Synthesis, 2013. 45: p. 1764-1784. 
126.  Zanda, M., et al., Efficient and regioselective 4-amino-de-chlorination of 2, 4, 6-
trichloropyrimidine with N-sodium carbamates. Tetrahedron Letters, 2000. 41(11): p. 
1757-1761. 
124.  Amita, T., M. Mridula, and V. Manju, Piperazine: the molecule of diverse 
pharmacological importance. Inter J of Ayurveda and Pharm, 2011. 2: p. 1547-1548. 
122.  Marchal, A., et al., Alkoxy‐5‐nitrosopyrimidines: Useful Building Block for the Generation 
of Biologically Active Compounds. European Journal of Organic Chemistry, 2010. 
2010(20): p. 3823-3830. 
100.  Paddison, P.J., et al., Short hairpin RNAs (shRNAs) induce sequence-specific silencing in 
mammalian cells. Genes Dev, 2002. 16(8): p. 948-958. 
 119 
 
101.  Zhou, H., X.G. Xia, and Z. Xu, An RNA polymerase II construct synthesizes short-hairpin 
RNA with a quantitative indicator and mediates highly efficient RNAi. Nucleic Acids Res, 
2005. 33(6): p .e62. 
102.  Hollstein, M., et al., p53 mutations in human cancers. Science, 1991. 253(5015): p. 49-53. 
100.  Levine, A.J., J. Momand, and C.A. Finlay, The p53 tumour suppressor gene. Nature, 1991. 
351(6326): p. 453-6. 
108.  Caron de Fromentel, C., et al., Rainbow trout p53: cDNA cloning and biochemical 
characterization. Gene, 1992. 112(2): p. 241-5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 111 
 
 
 
 
 
 
 
 
Chapter Six 
 
Appendices 
 
 
 
 
 
 
 
 
 
 111 
 
1H-NMR 300 MHz (DMSO) δ (ppm): 10.25 (s, 1H), 
7.51(d, 2H), 7.18 (d, 2H), 6.68 (s, 1H); 
M1
6.97 (s, 1H), 3.68 (t, 4H), 3.39 (t, 4H), 1.41 (s, 9H)
M2
 
 112 
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 تصميم و تحضير مشتقات البيريميدين ثلاثية التفرع كمثبطات لبروتين مرافق المنشط لمستقبلات
 الاستروجين
 
  دىمسوطلال " جمال محمد " ميران :  اعداد
 
 نجاجرة يوسف. د :اشراف 
 
 :ملخص
وتساهم إشارات ومستقبلات هرمون . أحد أكثر أنواع السرطانات شيوعا وتشخيصا بين النساء) CB(سرطان الثدي ر يعتب
حيث أن معظم هذه السرطانات تنشأ عن الزيادة المفرطة  في مستويات . في تطور سرطان الثدي) βRE، αRE(الاستروجين 
ويعتمد العلاج في هذه مثل هذه الحالات على تقليل . لهرمون الاستروجينالاستروجين الناتجة عن النشاط الزائد للتعبير الجيني 
لإيقاف ) SIA( مثبطات إنزيم الأروماتيز و) SEA(مستويات الاستروجين عن طريق استخدام مضادات هرمون الاستروجين 
على . لى هرمون الاستروجينالخلايا السرطانية  التي تعتمد  في نموها وانتشارها ع كبحو )RE( مستقبلات الاستروجين نشاط
الا أنها تفشل في كثير من الأحيان حيث تنشأ . الرغم من أن هذه  العلاجات لا تزال تمثل العلاج الأساسي لمرضى سرطان الثدي 
 .لدى المرضى مقاومة لهذه العلاجات تكون في غالبيتها غير قابلة للاستجابة 
حيث تعمل هذه . لمستقبلات الاستروجين rotavitcaoc((وتين مرافِق المنشِّطالتركيز على تصنيع مثبطات بر تم البحث في هىذا
مما يقدم . المركبات على وقف نشاط مستقبلات الاستروجين وكبح نمو خلايا سرطان الثدي بآلية مختلفة عن العلاجات السابقة
الحمض  اطاللازمة لارتب التغيرات التشكيليةمثبطات بروتين مرافق المنشط تعمل عن طريق اعاقة  . حلا لمشكلة المقاومة الحالية
 .لهرمون الاستروجين)  noisserpxe eneg(والتعبير الجيني) AND( النووي الريبوزي المنقوص الأكسجين
في هذا البحث تم تصميم وتصنيع مجموعة من المركبات بطريقة الاستبدال التسلسلي لذرات الكلور الموجودة في المركب 
 الفصل تقنيات كما تمت تنقية هذه المركبات باستخدام. ات وغيرهابمجموعات أخرى كالأمين) enidimiryporolhcirt-6,4,2(
كما تم   .ypocsortceps ))ISE( SM dna RI-TF ,RMN-C31 ,RMN-H1(عليها بواسطة  رفي، والتعرف ا الكروماتوغ
 لتقييمالخلايا  هذه  نوعين من حيث استخدم ). 13-mloM( سرطان الدم النخاعي الحاد  خلايا ضدالبيولوجي  للنشاط اختبارها
 لقد تمت تحديد). 35pالبروتين -hS( الخلايا معالآخرى مع  و ناقلات فارغة الخلايا مع باستخداممرة . 35pالبروتين  دور
 . 1-TSWتقنية   سلامة الخلايا باستخدام
 )53( 21YM(كبات المر أن   )31-mloM (السرطانية الخلايا على المركبات فعالية هىذه لاختبار الأولية نتائجالبينت 
في حين  ) 31-mloM(خلايا النوعين المستخدمين من خلايا   وتكاثر انتشار تثبيط في نشاطا فعالأظهرت    )62( 3YM((و
 .) 31-mloM( لم يظهر فعالية ملحوظة في تثبيط أي نوع من خلايا ))52(2YM(أن المركب 
